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2 SUMMARY 
The ribosome is a large macromolecular complex which mediates protein 
synthesis using messenger RNA (mRNA) as a template and aminoacyl-transfer 
RNA (tRNA) as a substrate. High accuracy of translation is essential for all living 
cells. Aminoglycoside antibiotics are used in clinical medicine to treat life-
threatening infections with gram-negative bacteria. Aminoglycosides target the 
highly conserved core structure of the ribosome, in particular the A-site, where 
they inhibit protein synthesis and prevent proper mRNA decoding.  
The objective of this thesis was to analyze how aminoglycosides affect the 
human ribosome, i.e. to study aminoglycoside-induced translation inhibition and 
misreading. As a possible consequence of ribosomal misreading we investigated 
cellular unfolded protein responses, in particular in mitochondria (UPRmt) and the 
endoplasmatic reticulum (UPRER). 
The first part of the thesis examines how different aminoglycosides affect 
translation. Towards this end we established a gain-of-function assay to measure 
the efficacy of translational and ribosomal accuracy. This we did in-vitro using 
Rabbit Reticulocyte Lysate and in-vivo using HEK293 cells. We observed a 
significant correlation when comparing in-vitro vs. in-vivo data between 
translation inhibition or misreading induction. Geneticin was identified as the 
most potent misreading inducer and translation inhibitor of the cytoribosome. 
However, no direct correlation was found between translation inhibition and 
misreading, i.e. these two mechanisms are not directly connected. For example, 
gentamicin and apramycin inhibit the cytoribosome to a similar extent in-vivo but 
in contrast to the high misreading induction of gentamicin no induction was 
observed with apramycin. In the second part of the thesis we wanted to study the 
influence of misreading and translation inhibition on UPRmt. As more than 99% of 
the mitochondrial proteins are produced in the cytosol but folded in the 
mitochondrium, misfolding of these imported proteins would be sensed inside the 
mitochondrium. The effect of aminoglycosides on UPRmt was analyzed by 
monitoring the induction of reporter genes driven by the mito-chaperone Hsp60 
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promoter and the mito-protease ClpP promoter. We found that there is a strong 
correlation between translation inhibition and levels of induction of the UPRmt. 
Finally, we studied the possible consequences of ribosomal misreading at the 
organism level. In murine cochlear explants, the aminoglycoside gentamicin 
induced CHOP, a prominent UPRER marker. In vivo, local aminoglycoside 
treatment caused high-frequency hearing loss in mice with a compromised 
UPRER, i.e. haplo-insufficient XBP1 (XBP1+/-) mice. This was accompanied by 
reduced densities of spiral ganglion cells and synaptic ribbons. 
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3 ZUSAMMENFASSUNG 
Das Ribosom ist ein grosser, makromolekularer Komplex, welcher Proteine 
herstellt unter Verwendung von messenger RNA (mRNA) als Vorlage und 
aminoacyl-transfer RNA (tRNA) als Substrat. Mit Aminoglykosiden werden 
Infektionen Gram-negativen Bakterien behandelt. Aminoglykoside binden an eine 
hochkonservierte Struktur des Ribosoms, die A-site, wodurch die Übersetzung 
von mRNA in Polypeptidketten ungenau, genannt Mistranslation, oder inhibiert 
wird.  
Ziel dieser Arbeit war die Untersuchung des Einflusses von Aminoglykosiden auf 
das menschliche Ribosom, das heisst die Inhibierung der Translation sowie 
Induktion von Mistranslation. Weiter untersuchten wir die Konsequenzen von 
misgefalteten Proteinen oder inhibierter Translation auf zellulärer Ebene. 
Im ersten Teil der Arbeit wird der Einfluss von verschiedenen Aminoglykosiden 
auf die Inhibition der Translation sowie die Induktion von Mistranslation 
untersucht. Wir haben dies mittels eines gain-of-function Assays getan, mit 
welchem wir die Genauigkeit des Ribosoms messen konnten. Durchgeführt 
wurden die Experimente mit Rabbit Reticulocyte Lysate, in-vitro, und HEK293 
Zellen, in-vivo. Wir konnten eine signifikante Korrelation zwischen in-vivo und in-
vitro Experimenten feststellen. Dabei wurde Geneticin als der stärkste Inhibitor 
als auch als der stärkste Induktor von Mistranslation identifiziert. Eine Korrelation 
zwischen Inhibition und Mistranslation konnte allerdings weder in-vivo noch in-
vitro festgestellt werden. So sind zum Beispiel die Aminoglykoside Gentamicin 
und Apramycin in-vivo vergleichbar bezüglich der Inhibition, doch während 
Gentamicin in hohem Masse eine Mistranslation induziert ist eine solche bei 
Apramycin nicht zu sehen. Im zweiten Teil dieser Arbeit untersuchten wir die 
mitochondrielle Unfolded Protein Response (UPRmt). Mehr als 99% der 
mitochondriellen Proteine werden im zytosol synthetisiert und erst danach im 
Mitochondrium gefaltet. Dort wird registriert falls ein Protein falsch gefaltet ist und 
eine UPRmt wird induziert. Der Effekt von Aminoglykosiden auf die UPRmt wurde 
mittels Reportergenen welche einen Hsp60 oder ClpP Promotor besitzen 
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gemessen. Die Inhibition der Translation und die Induktion der UPRmt hatten in 
hohem Masse korreliert. Im dritten Teil dieser Arbeit analysierten wir den Einfluss 
von Aminoglykosiden in lebendem Gewebe. In murinen chochlea Explantaten 
induzierte das Aminoglykosid Gentamicin CHOP, ein prominenter Marker für die 
Unfolded Protein Response des endoplasmatischen Retikulums (UPRER). In-vivo 
verursachten lokal angewendete Aminoglykoside den Verlust des Hörvermögens 
im hoch-frequenten Bereich bei Mäusen mit gestörter UPRER, d.h. XBP1 haplo-
insuffizient (XBP1+/-). Weiter wurden geringere Dichten der Spiralganglionen und 
synaptischen Bänder festgestellt. 
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4 INTRODUCTION 
4.1 The Ribosome  
4.1.1 Architecture of the Ribosome 
One of the most fundamental processes in life is protein synthesis. This basic 
process is carried out by the ribosome (from ribonucleic acid; soma – Greek for 
body), a large ribonucleoprotein complex found in all living cells. This complex 
has a high molecular weight, ranging from 2.5 MDa in prokaryotes to more than 4 
MDa in higher eukaryotes (Ben-Shem, Garreau de Loubresse et al. 2011, Lee 
and Gutell 2012). It is composed of a large and a small subunit, each containing 
ribosomal ribonucleic acids (rRNA) and ribosomal proteins (r-Proteins) (see 
Table 1). Despite large differences in size and compositional ratios of rRNA and 
r-Proteins, ribosomes from prokaryotes, eukaryotes and mitochondria share a 
highly conserved core structure. (see Figure 1 and Table 1).  
 
Tab. 1: Overview of the composition of the ribosome across the three kingdoms of life. 
 
 
Characteristics Bacteria Archaea Mitochondria Eukaryota
Ribosome Size 70S 70S 55S 80S
Small Subunit
Sedimentation coefficient 30S 30S 28S 40S
Mass (MDa) 0.8 0.8 1.2 1.4
rRNA 16S 16S 12S 18S
Number of r-proteins 20 28 33 32
Large Subunit
Sedimentation coefficient 50S 50S 39S 60S
Mass (MDa) 1.6 1.6 2.4 2.6
rRNA 23S, 5S 23S, 5S 16S 28S, 5.8S, 5S
Number of r-proteins 34 40 52 46
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Fig. 1: Comparison of the bacterial and the eukaryotic ribosome. A) 30S subunit of the bacterial ribosome. 
B) 40S subunit of the eukaryotic ribosome. C) 50S subunit of the bacterial ribosome. D) 60S subunit of the 
eukaryotic ribosome. Shown is in all pictures the solvent-exposed side of the subunits. Eukaryotic 
ribosomes are color-coded as follows: universally conserved proteins are shown in light blue, proteins 
present in archaea and eukarya are shown in gold and proteins and RNA elements exlusively present in 
eukarya in red. E-G) Comparison of the secondary structures of the (E) bacterial, (F) human cytosolic, and 
(G) mitochondrial A-site rRNA(boxed). Nucleotides of M. smegmatis and human cytosolic rRNA are 
numbered according to E.coli rRNA numbering. Pictures A – C adapted from (Ramakrishnan, Davies et al. 
1995), E – F from (Matt et al. 2010) 
								E	 	 	 F	 	 	 G	
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4.1.2 Mechanisms of Translation 
Genetically encoded information on messenger ribonucleic acids (mRNA) is 
decoded by amino acylated transfer ribonucleic acids (aa-tRNA) to produce 
amino acid chains. The two ribosomal subunits perform the core function of the 
ribosome: the tasks of tRNA recognition and polypeptide chain elongation (see 
Figure 2). The small subunit contains the aa-tRNA decoding site (A-site) where 
the codon-anticodon interaction takes place, i.e. the mRNA sequence is 
translated into an amino acid sequence. Each amino acid is specified by three 
bases (one codon) according to the genetic code (Ochoa 1967). In this code 
each amino acid is defined by one or more distinct codons and is delivered by a 
specific tRNA to the A-site. The large ribosomal subunit contains the peptidyl 
transferase center (P-site) where peptidyl transfer and hydrolysis reactions occur. 
 
 
 
 
 
 
Translation proceeds in three phases: initiation, elongation, and termination. In 
the initiation process of translation the small subunit of the ribosome binds a 
ternary complex consisting of initiation factors, Met-tRNA and GTP. During 
Fig. 2: The ribosomal core functions. The small and the large ribosomal subunits are shown in blue and 
ochre, respectively. The mRNA is shown in green, the tRNA bound to the ribosome in yellow and the 
emerging nascent polypeptide in pink. Picture from (Melnikov, Ben-Shem et al. 2012) 
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initiation, most eukaryotic mRNAs are translated by a cap-dependent 
mechanism, which requires recognition of the cap structure at the 5’ end of the 
mRNA by eIF4E complexed with eIF4G and eIF4A – the so-called eIF4F 
complex (Pestova, Kolupaeva et al. 2001). A pre-initiation complex consisting of 
a 40S ribosomal subunit loaded with eIF3, eIF1 and eIF1A, initiator fMet-tRNAMet, 
eIF2 and GTP binds the eIF4F-mRNA complex and scans along the 5’-UTR of 
the mRNA to reach the start codon, AUG. A free 60S ribosomal subunit, 
stabilized by eIF6 and eIF3, binds to the small subunit and subsequently the 
elongation cycle is launched (Hinnebusch 2014). This reaction requires an 
additional initiation factor, eIF-5, which hydrolyses the eIF-2-bound GTP, thereby 
releasing the initiation factors from the ribosome (see Figure 3). 
 
 
Fig. 3: Translation initiation in eukaryotic cells. Picture from (Voigts-Hoffmann, Klinge et al. 2012). 
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Fig. 4: Translation elongation in eukaryotic cells. Picture from (Dever and Green 2012) 
 
Elongation is assisted by elongation factors eEF1A and eEF2. The ribosome 
selects cognate tRNAs based on Watson-Crick complementarity between the 
mRNA and the tRNA anticodon. During elongation a ternary complex comprised 
of GTP, elongation factors, and aa-tRNA is delivered to the ribosomal A-site 
where it reacts with the peptidyl-tRNA in the ribosomal P-site. Forming a peptide 
bond the peptidyl-tRNA becomes bound to the aa-tRNA. The ribosome 
translocates to the next triplet, using the energy from elongation factor and GTP 
hydrolysis, i.e. the peptide-carrying tRNA is moved to the P-site and the 
deacetylated tRNA is shifted into the E-site remaining the A-site empty for the 
next cycle (see Figure 4).  
Elongation continues until the ribosome recognizes a stop codon in the A-site, 
UAA, UAG, or UGA, resulting in hydrolysis of the peptidyl tRNA mediated by the 
ternary complex consisting of the release factors eRF1 and eRF3, and GTP. 
Upon hydrolysis of GTP, eRF3 is released. The release of the completed 
polypeptide and dissociation of the ribosomal subunits is accompanied by 
binding of the ATPase ABCE1/Rli1 which supports accommodation of eRF1. 
During recycling, which is required to allow further rounds of translation, both 
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ribosomal subunits dissociate from the mRNA (Jackson, Hellen et al. 2012) (see 
Figure 5).  
 
 
Fig. 5: Translation termination in eukaryotic cells. The big ribosomal subunit is shown in light grey, the small 
subunit in dark grey. eRF1 is shown in blue, eRF3 is shown in brown, GTP is shown as a green circle and 
GDP is shown as red circle. Figure from (Weddle, Tu et al. 1995). 
 
4.1.3 Ribosomal Accuracy 
High accuracy of translation is critical as erroneous protein synthesis may result 
in protein misfolding or decreased protein functionality. However, high speed of 
protein synthesis is required to react appropriately to intra- and extra-cellular 
changes. Thus, translation should occur in a well-balanced manner addressing 
the requirements for both, speed and fidelity. During decoding the ribosome 
recognizes the geometry of codon-anticodon base pairing at the first two 
positions of the codon but monitors the third codon less stringently 
(Balasubramaian and Seetharamulu 1983). Codon-anticodon pairs with only one 
mismatch are referred to as near-cognate. Pairs with more than one mismatch 
are referred to as non-cognate. Binding of the ternary complex to the ribosomal 
A-site is reversible, and non-cognate ternary complexes usually dissociate at this 
stage (Gast, Peters et al. 1987). The specificity results from molecular 
interactions which take advantage of differences in the free energy (∆∆G) of 
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binding between cognate, near-cognate, and non-cognate substrates. Once the 
binding takes place in the A-site, rRNA nucleotides (G530, A1492, and A1493; E. 
coli numbering) interact with the mRNA-tRNA codon-anticodon minihelix. The 
rRNA nucleotide G530 moves from a syn- to an anti-conformation upon cognate 
tRNA binding. The rRNA nucleotides A1492 and A1493 are constantly moving, 
thus steadily opening and closing the A-site. The closed form of the A-site is 
stabilized by cognate tRNAs but not by near-cognate tRNA (see Figure 6). This 
stabilization of the flip-out of the nucleotides A1492 and A1493 operates as 
mechanism to ensure binding of a cognate tRNA. Upon tRNA binding, EF-Tu 
hydrolyses GTP while bound to the ribosome. This represents a branch point 
where either the aminoacyl end of the tRNA becomes available for peptidyl 
transfer (cognate tRNA), or the tRNA dissociates from the ribosome (near-
cognate tRNA). Overall, the error rates of translation in vivo have been estimated 
to be in the order of 10-3 to10-4 per codon (Ogle and Ramakrishnan 2005, Salas-
Marco and Bedwell 2005, Konstantinidis, Patsoukis et al. 2006, Fan-Minogue 
and Bedwell 2008, Vallabhaneni and Farabaugh 2009, Zaher and Green 2009, 
Keeling, Wang et al. 2012, Qin, Liu et al. 2012). 
 
 
 
 
 
 
Fig. 6: Structure of the bacterial ribosomal decoding A-site of the small subunit. A) Open/empty A-site 
with nucleotides A1492 and A1493 flipped into the minihelix 44 of the 16S rRNA. B) Closed A-site by 
binding of a cognate tRNA (yellow) to the mRNA (green). This interaction stabilizes the flip out of the 
nucleotides A1492 and A1493 (blue) and the flip from syn- to anti-conformation of G530 (blue). Picture 
adapted from (Laurberg, Asahara et al. 2008). 
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4.1.4 Aminoglycosides 
As protein synthesis is an indispensable process for all living cells, it makes a 
formidable target for antimicrobial substances. Many antibiotics target the 
ribosome, mainly by binding to the rRNA of either the small or the large 
ribosomal subunit. These classes of antibiotics include aminoglycosides, 
spectinamides, macrolides, lincosamides, tetracyclines and oxazolidinones.  
Aminoglycosides are bactericidal antimicrobials, water-soluble and relatively 
stable at different temperatures and pHs (Lynch and Puglisi 2001, Dandliker, 
Pratt et al. 2003, Szychowski, Kondo et al. 2011, Matt, Ng et al. 2012). The term 
“aminoglycoside” is derived from the chemical structure of these compounds, 
which are made up of amino groups attached to glycosides. These antibiotics 
occur naturally and are isolated from Micromonospora (suffix –micin) or 
Streptomyces (suffix –mycin). Aminoglycosides share a common neamine core 
consisting of a glucopyranosyl (ring I) glycosidally linked to position C4 of the 
hexose 2-deoxystreptamine (ring II). Ring II is substituted with additional 
aminosugars on either C5 (4,5-Aminoglycosides, ring III and IV) or C6 (4,6-
Aminoglycosides, ring III). There are also unusual aminoglycoside-structures, 
e.g. apramycin with a monosubstituted 2-deoxystreptamine and a bicyclic sugar 
moiety or hygromycin B with its ring III resulting from a dual ether linkage 
between ring II and ring IV (see Figure 7).  
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Fig. 7: Chemical structure of 2-deoxystreptamine aminoglycosides used in this study. Ring I (2-
deoxystreptamine, red) and ring II build the backbone of this class of antibiotics, a common neamine core. 
A) 4,5-aminoglycosides paromomycin and neomycin. B) 4,6-aminoglycosides with various substituents. Note 
that amikacin contains an additional (l)-α-hydroxy-γ-aminobutyric amide (L-HABA chain )at the aminogroup 
4,5-AG 4,6-AG 
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of C1 of ring II (Kondo, Francois et al. 2006). C) Apramycin, and D) Hygromycin B, compounds with a 
unique structure within the class of aminoglycosides.  
 
4.1.5 Aminoglycosides and Misreading 
Aminoglycosides bind reversibly to the A-site of bacterial ribosomes where they 
make extensive interactions with the rRNA of the small ribosomal subunit internal 
loop containing A1492 and A1493 (see Figures 3C) (Carriere, Vijayabaskar et al. 
2002, Borovinskaya, Shoji et al. 2008, Fan-Minogue and Bedwell 2008, 
Szaflarski, Vesper et al. 2008, Tselika, Konstantinidis et al. 2008, Kramer, 
Vallabhaneni et al. 2010, Fernandez, Malchiodi et al. 2011, Matt, Ng et al. 2012, 
Demirci, Murphy et al. 2013). Ring I of aminoglycosides is located in the internal 
loop of the rRNA formed by nucleotides A1408, A1492, A1493 and the C1409-
G1491 base pair. Two hydrogen bonds are formed by ring I to A1408, mimicking 
a pseudo base-pair. Further, ring I participates in a stacking interaction with 
G1491. The hydroxyl groups at position O3’ and O4’ of ring I form additional 
hydrogen bonds to the phosphates of A1492 and A1493 (see Figure 8A). Ring II 
of the aminoglycosides is located between nucleotides A1493, G1494, and 
U1495. The 1-aminogroup of ring II interacts with the O4 of U1495 and the 3-
aminogroup interacts with N7 of G1494. (Blanchard, Fourmy et al. 1998, Slezak, 
Persky et al. 1998, Pfister, Hobbie et al. 2003, Francois, Russell et al. 2005). The 
positioning of aminoglycosides ring I and II is virtually universal at this position. 
The rings III and IV of 4,5-aminoglycosides or ring III of 4,6-aminoglycosides 
make additional interactions with the helix 44 of the A-site (Hobbie, Bruell et al. 
2006, Hobbie, Pfister et al. 2006, Hobbie, Kalapala et al. 2007, Matt, Ng et al. 
2012, Dudek, Romanowska et al. 2014, Perez-Fernandez, Shcherbakov et al. 
2014). For 4,5-aminoglycosides ring III and IV reach down the drug binding 
pocket towards G1491 whilst for 4,6-aminoglycosides ring III reaches up the drug 
binding pocket towards U1406 (see Figure 8B). Crystal structures of ribosomes 
with aminoglycosides show a flip-out of A1492 and A1493. Thus, 
aminoglycosides stabilize the local conformational changes in the decoding site 
as if a cognate tRNA is present (Laurberg, Asahara et al. 2008). Mimicking the 
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binding of a cognate tRNA, this stabilized conformational alteration would allow 
the incorporation of a near-cognate tRNA and result in misreading. As 
aminoglycosides bind to the evolutionary conserved core structure of the 
ribosome, these chemicals may not only exert an antimicrobial effect but may 
also bind to the eukaryotic cytosolic ribosomes (Duff 1992).  
 
4.1.6 Protein Quality Control and Cellular Stress Response in Eukaryotes 
Newly synthesized proteins are usually folded directly after translation either in 
the cytosol (cellular proteins) or in the endoplasmatic reticulum (ER) (membrane 
and secreted proteins) (Pfanner, Rassow et al. 1990, Hendrick and Hartl 1995, 
Trombetta and Parodi 2003). Folding is supported by molecular chaperones; 
proteins that interact, stabilize or help a non-native protein to reach its native 
conformation but are not present in the final functional protein. Eukaryotic cells 
survey the proper protein folding and eliminate misfolded proteins to restore 
protein homeostasis. In general there are three different response types known: 
i) cytosolic heat shock response (HSR), ii) ER unfolded protein response 
(UPRER) and, iii) mitochondrial unfolded protein response (UPRmt) (Vujanac, 
Fenaroli et al. 2005, Voellmy and Boellmann 2007, Lee, Liu et al. 2009, Jacobs 
and Marnett 2010, Chakrabarti, Chen et al. 2011). The latter will be discussed in 
more detail in section 4.2.4.  
The cytosolic heat shock response induces four different heat shock factors 
(HSF1-4) in higher eukaryotes with HSF1, a transcriptional regulator, as the 
major player. Under normal conditions, HSF1 is mostly bound to the chaperones 
heat shock protein 70 (HSP70) and HSP90 to build an inert monomeric complex. 
Under stress conditions, e.g. increased load of denatured cytosolic proteins, 
HSF1 is displaced from chaperones HSP70 and HSP90 which are recruited to 
exert their chaperone function. Additionally, HSF1 is posttranslationally modified 
including phosphorylation/dephosphorylation, acetylation/deacetylation, 
sumoylation and the inactive monomeric form of HSF1 is shifted into an active 
trimeric form and translocated to the nucleus. This trimeric form is competent for 
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Fig. 8: Tertiary structure of the A-site in complex with aminoglycosides. A) Ring I of paromomycin (yellow) 
builds hydrogen bonds (red dashed) with the A-site nucleotides A1408 and A1493. There is also a stacking 
interaction between ring I and G1491. Interactions of O3’ and A1492 are not shown. Adapted from (Perez-
Fernandez, Shcherbakov et al. 2014) B) Tobramycin (ring III in red) and paromomycin (ring III and IV in 
blue), the common neamine core is shown in yellow. Picture adapted from (Akbergenov 2011). 
A 
B 
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DNA binding at the promoter sequences of the 5’ region of hsp genes. These 
conserved sequences are known as heat shock elements (HSE). When 
proteostasis is restored excessive HSPs inactivate HSF1 and transcription of 
HSPs is stopped (see Figure 9) (Adachi, Liu et al. 2009, Lee, Liu et al. 2009). 
 
 
Fig. 9: Schematic overview of the transcriptional regulation of the cytosolic heat shock response. (1) Inert 
monomeric complex of Hsp70, Hsp90 and HSF1. (2) Cellular stress increasing the load of un- or misfolded 
proteins. (3 and 4) Misfolded proteins bind to Hsp70 and Hsp90, resulting in the displacement of HSF1. (5 
and 6) Trimerized HSF1 translocates to the nucleus, undergoing posttranslational modifications. (7 and 8) 
Induction of transcription of numerous hsp genes, including Hsp70 and Hsp90, by binding of the activated 
HSF1 to the HSE resulting in translation of HSPs. (9) After the load of non-native proteins decreases HSF1 
shifts back into its inert monomeric form. N = native protein, U = unfolded protein. Figure adapted from 
(Vabulas, Raychaudhuri et al. 2010).  
 
In the UPRER, three distinct transmembrane sensor systems are known which all 
use the chaperone BiP as a regulator. In proteostasis, the transmembrane 
domains of the three sensors are associated with BiP. Upon accumulation of 
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unfolded proteins in the ER-lumen BiP dissociates to exert its chaperone activity 
and kicks of UPRER (see Figure 10).  
 
Fig. 10: Schematic overview of the three distinct sensor systems of the unfolded protein response in the ER. 
Figure from (Cyr and Hebert 2009). 
 
The first sensor system is PERK (Protein kinase RNA (PKR)-like ER Kinase), a 
type I transmembrane protein with kinase activity. PERK is composed of an ER 
luminal stress sensor and a cytosolic protein kinase domain. Dissociation of BiP 
from the N-terminus of PERK initiates dimerization and autophosphorylation of 
the kinase domain. Activated PERK phosphorylates eIF2α which leads to three 
downstream effects, i) a generally attenuated translation initiation to decrease the 
protein folding load, ii) expression of pro-survival genes, e.g. cellular inhibitor of 
apopotosis (cIAP) and iii) an increased clearance of the accumulated proteins 
from the ER, e.g. by ER-associated degradation. In this case, ER α-mannosidase 
I removes the terminal mannose residue from oligosaccharides attached to 
proteins. Subsequently, misfolded proteins are transported out of the ER back 
into the cytosol. However, the retro-translocon responsible for this process is 
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unclear (Tsai, Ye et al. 2002). Once the unfolded or misfolded proteins are in the 
cytosol they are degraded by the ubiquitin proteasome system (Hershko, 
Ciechanover et al. 2000). Decreased protein translation is not universal; genes 
with internal ribosomal entry site (IRES) sequences in the 5’ untranslated regions 
can bypass the eIF2α translational block and induce the expression of pro-
survival functions such as amino acid transport or protein secretion by ATF4 
(Verfaillie, Rubio et al. 2012). The second sensor system is ATF6, (Activating 
Transcription Factor 6), a type II transmembrane domain protein with a basic 
leucin zipper (bZIP) transcription factor in its cytoplasmic domain. This 
transcription factor induces transcription of specific UPR genes (Chakrabarti, 
Chen et al. 2011, Smith, Granell et al. 2011). ATF6 is activated by undergoing 
intramembrane proteolysis. The cleavage at a juxtamembrane site allows the 50 
kDa transcriptional domain of ATF6 to be translocated to the nucleus. There, it 
regulates expression of genes containing ATF/cAMP response elements or ER 
stress response elements. Cleaved ATF6 induces a gene expression program 
together with other transcription factors and regulators, e.g. nuclear factor Y (NF-
Y). Like this, chaperone activity and degradation of unfolded proteins can be 
increased. For example, ATF6 upregulates the expression of BiP or the ER-
degradation-enhancing alpha-mannosidase-like protein (EDEM1). Additionally, 
ATF6 induces the expression of the X-box-binding protein 1 (XBP1) which 
regulates the expression of chaperones (Chakrabarti, Chen et al. 2011). The 
third sensor system is IRE1 (Inositol-Requiring Protein-1), a 100 kDa type I 
transmembrane protein with splicing activity. The N-terminus of IRE1, located in 
the ER-lumen, senses unfolded or misfolded proteins. BiP dissociates and IRE1 
proteins form a complex which acts specifically as an RNase which cleaves a 26-
nucleotide intron from the XBP1-mRNA to generate a 41 kDa frameshift variant 
(sXBP1) that acts as a potent transcription factor for UPR genes with pro-survival 
and pro-apoptotic effects (Paschen 2003, Gupta, Deepti et al. 2010, Shao, Shan 
et al. 2014). 
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4.2 Mitochondria 
4.2.1 Organization and Function 
Mitochondria are double-membrane bound organelles which range in size from 
0.5 to 2 µm in diameter. The number of mitochondria per cell is highly variable, 
depending on the organism or tissue – up to several thousand mitochondria per 
cell have been observed. Mitochondria are often referred to as cellular power 
plant reflecting their high metabolic activity for the generation of adenosine 
triphosphate (ATP) by oxidative phosphorylation (OXPHOS). Further important 
roles are the involvement in cell cycle control, calcium (Ca2+) homeostasis, 
generation of FeS clusters as essential cofactors for mitochondrial and cytosolic 
proteins, and fatty acid oxidation (Gray, Burger et al. 1999, Lang, Gray et al. 
1999, Lang, Seif et al. 1999). It is well established that mitochondria evolved from 
a single endosymbiotic event around two billion years ago where an α-
proteobacterium was engulfed by a precursor of the modern eukaryotic cell [9]. In 
other words a prokaryotic organism with highly efficient energy production 
machinery was taken up by a eukaryotic cell and kept as an organelle. Thus, 
mitochondria possess their own genome, which is often circular and present in 
one to many copies (Lohse, Drechsel et al. 2007, Preuten, Cincu et al. 2010, 
Copeland and Longley 2014, St John 2014). During evolution, most of the 
genomic material of the α-proteobacterium progenitor was rapidly lost or 
transferred to the nuclear genome of the host, e.g. all of the complex II protein 
subunits from OXPHOS. This event is known as endosymbiotic gene transfer 
(EGT) and reduced the mitochondrial genome content from several thousand 
protein coding genes, depending on the organism, down to 3 to 67 protein coding 
genes in present day mitochondria (Chevallet, Lescuyer et al. 2006). In humans, 
over 95% of the mitochondrial proteome is nuclear encoded and has to be 
translated in the cytosol and subsequently imported into the mitochondrion. The 
mitochondrial genome consists of a multicopy, circular, double-stranded DNA 
molecule of 16.6 kb. It encodes 13 essential polypeptides of the OXPHOS 
system, i.e. components of complex I, III, IV and the ATP synthase (see figure 
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11) (Lang, Gray et al. 1999). In addition to the proteins, mitochondria encode 22 
tRNAs and the two rRNAs used for the mitoribosomal subunits. The remainder of 
the mitochondrial proteome is encoded by the nuclear genome, translated in the 
cytosol and imported into each mitochondrion. At present the total proteome of 
mitochondria is suggested to be 1100 - 1400 distinct gene loci encoding 
mitochondrial proteins (Taylor, Fahy et al. 2003, Meisinger, Sickmann et al. 2008, 
Meyer, Taylor et al. 2008, Pagliarini, Calvo et al. 2008, Lotz, Lin et al. 2014).  
 
 
 
Fig. 11: Mitochondrial respiratory chain and oxidative phosphorylation system. Each colored hexagon 
represents a polypeptide product of a single mitochondrial gene. Picture from (Ramakrishnan 1997) 
 
Mitochondria are composed of four compartments: the outer and inner 
membranes, the intermembrane space (IMS), and the matrix, each of which has 
its special tasks and specificities. The outer mitochondrial membrane (OMM) 
serves as a first barrier of the compartmentalized organelle and resembles other 
eukaryotic membranes. The presence of voltage-dependent anion channels 
(VDAC) and the protein import machinery make it permeable to metabolites and 
proteins (Kay, Li et al. 1997, Ghosh, Pandey et al. 2007, Ahmed, Muhammed et 
al. 2010). (Hajek and Bedwell 1994, Raja and Greenberg 2014). The inner 
mitochondrial membrane (IMM) itself is highly structured and differentiated into 
compositionally and functionally distinct regions. Lipid trafficking, mitochondrial 
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protein import and respiratory chain complex assembly take place within the 
inner boundary region while the cristae, invaginations that penetrate the matrix, 
house assembled respiratory complexes where ATP synthesis via OXPHOS 
takes place. Within the IMS mainly exchange of lipids, ions and various 
metabolites is taking place but most importantly it is the site where the 
electrochemical gradient is being built up by pumping protons across the proton-
impermeable IMM into the IMS. The innermost compartment is completely 
enclosed by the IMM and called the matrix. It harbors the mitochondrial DNA, is 
the place of the tricarboxylic acid cycle (TCA cycle), production of reactive 
oxygen species (ROS) and control of autophagy and apoptosis (Glick, Beasley et 
al. 1992, Kaldi and Neupert 1998, Gordon, Dancis et al. 2000, Hoogenraad and 
Ryan 2001).  
The main task of mitochondria, ATP generation, is mainly done by oxidation of 
the products from cytosolic glycolysis, pyruvate and NADH. Each pyruvate 
molecule is actively transported from the cytosol into the matrix of the 
mitochondria. There, combined with acetyl-CoA, it serves as substrate in the 
TCA cycle to produce the reduced cofactors NADH and FADH2, and in addition 
one ATP. The reduced cofactors are then used as source of energy for oxidative 
phosphorylation by the electron transport chain (ETC). There, protons from the 
cofactors are pumped over the IMM into the IMS to generate a membrane 
potential. When returning into the matrix the protons pass the ATP synthase and 
per three protons one ATP is generated. Overall, eukaryotic cells are able to 
produce ~30 molecules of ATP per molecule of glucose (Yonally and Capaldi 
2006) (see Figure 12). 
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Fig. 12: Overview of ATP production in mitochondria (Wikipedia 2007). 
 
4.2.2 Diseases Related to Mitochondrial Malfunction 
Along with the importance of these organelles are risks for diseases or disorders 
caused by malfunctional mitochondria (see Table 3). The vast majority of 
mitochondria associated diseases are maternally inherited. Mitochondria and 
therefore mitochondrial DNA (DNAmt) are derived from the ovum, as the sperm's 
mitochondria enter the egg but are immediately ubiquitinated and destructed 
inside the embryo (Raurell, Southern et al. 1997). Diseases and malfunctions can 
either occur because of large-scale DNAmt rearrangements or point mutations. 
An example for a disease associated with a point mutation of DNAmt is 
sensorineural deafness. Single nucleotide alterations of the 12S rRNA, A1555G 
or C1494T, were identified as a source of nonsyndromic deafness (Tuggle, Birket 
et al. 2014). These mutations both locate to a highly conserved part of the 12S 
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rRNA and form a similar RNA base-pair (compare secondary structures in Figure 
1G). This region is essential for the decoding function of the A-site of the small 
subunit of the mitochondrial ribosome (Milon and Rodnina 2012). The clinical 
phenotype produced by these mutations range from normal hearing to severe 
congenital deafness, most probably depending on the nuclear background 
(Aeffner, Abdulrahman et al. 2013). In addition, patients carrying these mutations 
are particularly susceptible to aminoglycoside-mediated ototoxicity (Kramer and 
Hopper 2013). Sequence analyses of the mitochondrial genome in patients with 
aminoglycoside induced ototoxicity have shown that the two mutations A1555G 
and C1494U of the 12S rRNA account for up to 33% of the cases (Dutnall, Tafrov 
et al. 1998). 
 
 
Tab. 3: Frequent diseases associated with mitochondria. Adapted from (Andre Mattman 2011) 
Syndrome and features Genetics 
Leigh syndrome 
Neonatal subacute encephalopathy with bilateral 
symmetric midbrain and basal ganglia necrosis on MRI 
Autosomal recessive, 
mitochondrial DNA, X-
linked (SURF1) 
MERRF 
Myoclonic epilepsy with ragged-red fibres on muscle 
biopsy 
Mitochondrial DNA, 
mito-tRNAs 
MELAS 
Mitochondrial encephalopathy with lactic acidosis and 
stroke-like episodes 
Mitochondrial DNA, 
mito-tRNAs 
MIDD 
Maternally inherited diabetes and deafness 
Mitochondrial DNA, 
mito-tRNAs 
Kearns-Sayre syndrome 
External ophtalmoplegia, pigmentary retinopathy, 
elevated CSF protein, cerebellar ataxia, and cardiac 
conduction defects 
Mitochondrial DNA, 
5kb deletion (12 
genes) 
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Nonsyndromic Deafness 
Mild to severe permanent hearing loss caused by damage 
to structures in the inner ear 
Mitochondrial DNA 
(MT-RNR1) 
 
4.2.3 Mitochondrial Protein Import 
As much as 10% to 15% of the nuclear genes of eukaryotic organisms encode 
for mitochondrial proteins which are translated on cytosolic ribosomes and 
subsequently imported into the mitochondrion (Kaldi and Neupert 1998, Gray, 
Burger et al. 1999, Cameron, Hurd et al. 2005, Copeland and Longley 2014). 
Thus, highly specific and efficient import machineries are essential to guide these 
proteins into the mitochondrion and sort them to the diverse compartments. To 
do so, mitochondrial proteins have precursor-recognizing receptors, membrane 
spanning pores and proteolytic enzymes that mediate import of precursor 
proteins. The mitochondrial precursor proteins contain various targeting 
sequences, depending on their final destination in the mitochondria (see Figure 
13). 
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Fig. 13: Targeting and Sorting Signals of Mitochondrial Precursor Proteins. Three main classes of signals 
are shown: A) Presequences which are usually cleaved off by MPP and IMP, B) Noncleavable signals of 
hydrophobic proteins, and C) Internal signals for IMS.Picture from (Ramakrishnan, Southern et al. 1998). 
 
Matrix proteins usually have an N-terminal presequence termed matrix-targeting 
sequence (MTS) consisting of 10 to 80 amino acids. They often form amphipathic 
α-helices which are positively charged and have a hydrophobic surface. After 
import the MTS is cleaved off by a mitochondrial processing peptidase (MPP) 
(Gordon, Dancis et al. 2000, Ozawa, Sako et al. 2003). IMM proteins contain 
either hydrophobic internal targeting signals or presequences followed by a 
hydrophobic membrane anchor sequence that retains the protein in the IMM. 
Typically these signals remain part of the mature protein (Doonan, Marra et al. 
1984, Pfaller, Steger et al. 1988, Glick, Beasley et al. 1992). IMS proteins were 
also shown to have presequences followed by a hydrophobic membrane anchor 
(Doonan, Marra et al. 1984, Pfaller, Steger et al. 1988, Glick, Beasley et al. 1992, 
Kaldi and Neupert 1998). In contrast to IMM proteins, these presequences are 
cleaved off by MPPs and an inner membrane protease to release them into the 
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IMS. Most OMM proteins contain a non-cleavable targeting sequence followed by 
a long hydrophobic stretch. The presequence guides the protein to the 
mitochondria and the hydrophobic stretch is responsible for the insertion to the 
OMM (Glick, Beasley et al. 1992, Kaldi and Neupert 1998, Gordon, Dancis et al. 
2000, Hoogenraad and Ryan 2001).  
 
 
Fig. 14: The four main complexes of the mitochondrial protein import machinery. Figure adapted from (Rettig 
2011). 
 
In most eukaryotes four distinct high molecular weight protein complexes exist 
within the OMM and the IMM to mediate protein translocation (see Figure 14). 
The translocase of the outer mitochondrial membrane (TOM) is the main entry 
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gate for essentially all proteins that have to be imported. It is built out of 7 
proteins around a pore-forming β-barrel protein (Ryan, Wagner et al. 2000, Kato 
and Mihara 2008). A second OMM translocase complex, also carrying a β-barrel 
protein as core component, is a sorting and assembly machinery (SAM). The 
SAM complex inserts proteins into the OMM, after import of proteins into the IMS 
(Doonan, Marra et al. 1984, Glick, Beasley et al. 1992, Kaldi and Neupert 1998). 
Within the IMM two translocases of the inner mitochondrial membrane (TIM) 
exist, TIM22 and TIM23. The first one, TIM22, is thought to insert hydrophobic 
carrier proteins into the IMM. The core of the second complex, TIM23, is built of 
the translocase channel Tim23, the precursor recognition and channel gating 
subunit Tim50, and Tim17 which is involved in motor recruitment and lateral 
preprotein sorting (Doonan, Marra et al. 1984, Glick, Beasley et al. 1992, Kaldi 
and Neupert 1998, Davis, Sepuri et al. 2000). Through coupling respiratory chain 
complexes III and IV with the TIM23 complex the membrane potential around 
TIM23 is increased, giving the driving force for protein translocation by exerting 
an electrophoretic effect on positively charged MTS. For complete translocation 
over the IMM into the matrix an additional driving force next to the electrophoretic 
effect is necessary. This is provided by the ATP-driven mitochondrial heat shock 
protein mtHsp70. Once the proteins are imported into the matrix their 
presequences are cleaved off by MPPs and the proteins are folded into their 
native form by matrix localized chaperones (Sirrenberg, Bauer et al. 1996, 
Gordon, Dancis et al. 2000, Yoneda, Benedetti et al. 2004). 
 
4.2.4 Mitochondrial Quality Control and Unfolded Protein Response 
Several factors challenge the homeostasis of the mitochondrial protein-folding 
environment including complexities in mitochondrial biogenesis, e.g. reactive 
oxygen species (ROS) that are generated within mitochondria, environmental 
factors such as changes in temperature, or exposure to toxins (Haynes and Ron 
2010). In addition, protein synthesis in the cytosol and the mitochondria have to 
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be synchronized as ETC complexes I, III, IV and the ATP synthase contain 
subunits encoded and produced in different parts of the cell, i.e. mitochondria or 
nucleus and cytosol (Haynes and Ron 2010). To promote efficient mitochondrial 
protein folding and complex assembly, mitochondria have a dedicated repertoire 
of molecular chaperones located in both the IMS and matrix. For example, the 
nuclear encoded Hsp60 chaperonin is located in the matrix, and consists of both 
Hsp60 and Hsp10 subunits which form a barrel-shaped complex. The Hsp60 
chaperonin primarily facilitates the folding of relatively small, soluble monomeric 
proteins (Baena-Lopez, Alonso et al. 2008, Felk, Ohrt et al. 2010, Rocha, 
Ferreira et al. 2011). In addition to molecular chaperones, mitochondria house 
several quality control proteases, e.g. ClpXP or Lon, that recognize and degrade 
those proteins that fail to fold or assemble correctly (Missiakas, Schwager et al. 
1996, Smakowska, Czarna et al. 2014). The importance of maintaining the 
mitochondrial protein-folding environment can be emphasized by diseases 
associated with a compromised balance of the mitochondrial proteome. For 
example, mutations of Hsp60 or in the mitochondrial quality control protease 
Paraplegin cause spastic paraplegia, and the mitochondria-specific translation 
inhibitors paraquat and rotenone as well as an Htra2-deletion cause Parkinson’s-
like symptoms (Moisoi, Klupsch et al. 2009). In addition to a variety of diseases, 
loss of mitochondrial protein homeostasis has been associated with the aging 
process (Pan 2011, Gregersen, Hansen et al. 2012, Cuadrado-Tejedor, 
Cabodevilla et al. 2013, Kumar, Gibbs et al. 2013). 
In response to the accumulation of unfolded or misfolded proteins, cells mount a 
mitochondrial unfolded protein response (UPRmt). The UPRmt is an organelle 
specific pathway with no direct connection to the UPR of the ER (Zhao, Wang et 
al. 2002, Yoneda, Benedetti et al. 2004, Horibe and Hoogenraad 2007). UPRmt is 
a mitochondria-to-nuclear signal transduction pathway resulting in the induction 
of mitochondrial protective genes including mitochondrial molecular chaperones 
and proteases to re-establish protein homeostasis within the mitochondrial 
protein-folding environment. The signal transduction mechanism from 
mitochondria to the nucleus is still a topic of ongoing research. The transcription 
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factors CHOP and C/EBPβ are required for Hsp60 transcription (see Figure 15). 
The presence of an activator protein-1 (AP1) site was revealed by analysis of the 
promoters of CHOP and C/EBPβ and hence suggested the presence of the Jun 
transcription factor which makes the involvement of JNK2, a kinase upstream of 
Jun, likely. Jun becomes phosphorylated upon mitochondrial stress whilst a 
JNK2 inhibitor attenuates the response. However, it is unlikely that CHOP, 
C/EBPβ and Jun are the only transcription factors involved in the UPRmt as the 
CHOP binding sites involved in mitochondrial stress response are flanked by two 
additional conserved sequences, the so-called mitochondrial UPR elements 
(MUREs) (Zhao, Wang et al. 2002). 
 
Fig. 15: Mitochondrial UPR signaling in mammalian cells. Figure taken from (Haynes and Ron 2010) 
 
Much more is known about the signaling pathway of UPRmt in C. elegans 
(Haynes, Petrova et al. 2007, Haynes and Ron 2010, Haynes, Yang et al. 2010, 
Baker, Nargund et al. 2012, Nargund, Pellegrino et al. 2012, Haynes, Fiorese et 
al. 2013, Pellegrino, Nargund et al. 2013). The protease ClpXP degrades 
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unfolded or unassembled proteins into peptides of approximately 8-20 residues 
which are pumped across the inner membrane by the ABC-transporter HAF-1 
and then across the outer membrane to the cytosol. It was suggested that the 
peptide efflux weakens mitochondrial import (Nargund, Pellegrino et al. 2012). 
The main UPRmt regulator, the transcription factor ATFS1, contains both nuclear 
localization/export (NLS) and mitochondrial targeting sequences (MTS). Under 
protein homeostasis conditions ATFS1 is transported into the mitochondria and 
degraded (Nargund, Pellegrino et al. 2012). However, because of impaired 
protein import due to proteotoxic stress in mitochondria leads to translocation of 
ATFS1 to the nucleus. Further, the homeobox proteins DVE-1 and UBL-5 form a 
complex and bind to the hsp-60 promoter to promote ATFS-1 binding to activate 
transcription. Transcriptional upregulation of mitochondrial chaperone genes 
leads to their subsequent import into mitochondria, thus relieving stress and re-
establishing mitochondrial protein homeostasis (see Figure 16). ATFS1 also 
functions to increase the expression of proteins involved in mitochondrial import, 
ROS detoxification and protection against mitochondrial dysfunction (Nargund, 
Pellegrino et al. 2012). 
 
 
Fig 16: Model of the UPRmt in C. elegans. Figure taken from (Haynes and Ron 2010). 
  
ATFS ATFS
ATFS
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5 RESULTS 
5.1 Aminoglycoside-Induced Misreading  
5.1.1 Codon Selection for Gain-of-Function Assay 
Missense errors during protein synthesis result from incorrect codon recognition 
(Daviter, Gromadski et al. 2006). Not all codons are error prone and not all 
codons are equally sensitive to be misread on aminoglycoside treatment (Kramer 
and Farabaugh 2007). The ideal codon for the experimental analysis of 
aminoglycoside induced misreading is not error prone but is mistranslated when 
a misreading inducing drug is applied.  
Several systems have been used to analyze the frequency of erroneous 
decoding, e.g. lysine incorporation, radiolabelling, 2D-gel electrophoresis, and 
restoring enzymatic activity of reporters (Edelmann and Gallant 1977, Edelmann 
and Gallant 1977, Parker 1989, Soslau and Parker 1989, Cornut and Willson 
1991, Kramer and Farabaugh 2007, Ortego, Whittenton et al. 2007). For our 
purpose we decided to use the gain-of-function assay previously described by 
Kramer et al. (Kramer and Farabaugh 2007) (see Figure 17).  
 
 
Fig. 17: Schematic procedure of the in vitro dual luciferase assay. In vitro translation, i.e. RRL ribosomes 
translating the mRNAs of Fluc and Rluc. 
 
Measurements of relative luminescence units (RLU) of firefly luciferase serve as 
basis for this assay. To determine drug-mediated translation inhibition, the 
antibiotic was titrated and the reduction of RLUs was plotted. By preparing such 
In-vitro translation reaction: 
Ribosomes from rabbit 
reticulocyte lysate  
mRNA Rluc 
mRNA Fluc 
Amino acids 
RNase inhibitor 
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curves the IC25, IC50 and IC75 values can be elicited, i.e. the drug 
concentrations at which the inhibition of translation activity is 25%, 50%, or 75%, 
respectively.  
Residues H245 or K529 in the catalytic center are the amino acids responsible 
for orientation of the substrates luciferin and ATP in the active site (Branchini, 
Magyar et al. 1998, Branchini, Murtiashaw et al. 2000). To determine misreading 
we used a mutated firefly luciferase. By mutating the cognate wild type codon 
H245CAC or K529AAA to a near-cognate codon the activity of the firefly luciferase 
is significantly reduced. Mutations were introduced in the active site, for a 
summary see Table 4. Misreading of these codons would restore firefly luciferase 
function; hence such mutations can be used to compare the rate of decoding 
errors. As a reference a wild type renilla luciferase was used in all reactions.  
Near-cognate mutations at codon K529AAA decreased enzymatic activity up to 
2500-fold compared to wildtype firefly luciferase (see Table 4 and Figure 18). To 
test which mutation best serves our purpose, we used the aminoglycoside 
paromomycin, which is known to induce misreading (Davies, Gorini et al. 1965, 
Palmer and Wilhelm 1978, Mironova, Provorov et al. 1982, Eustice and Wilhelm 
1984, Tuite and McLaughlin 1984). When rabbit reticulocyte lysate (RRL) 
ribosomes were treated with 10 µM paromomycin near-cognate mutant 
luciferases showed a relative increase of signal intensity of 3.9-fold up to 9.1-fold 
as compared to luciferases produced from untreated ribosomes (see Table 4 and 
Figure 18).  
Near-cognate mutations at codon H245CAC decreased the enzymatic intensity up 
to 3200-fold compared to the wildtype firefly luciferase (see Table 4 and Figure 
18). Treatment of ribosomes with paromomycin resulted in a relative increase of 
the firefly luciferase activity of 4.2-fold and 25.1-fold for near-cognate codons 
H245GAC and H245CGC, respectively. Near-cognate codons H245CAG and 
H245UAC showed no increase of relative signal intensity (see Table 4 and Figure 
18) as they are naturally error prone, i.e. these codons are highly misread without 
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any antibiotic treatmet of the ribosome. As a negative control the non-cognate 
mutant H245AGA was used.  
Based on these results, further experiments to measure aminoglylcoside induced 
mistranslation were conducted with a reporter construct containing the near-
cognate H245(CAC  CGC) nucleotide point mutation. 
 
Tab. 4: List of the mutated codons and corresponding values of firefly activity (RLU) with the corresponding 
standard error of the mean (SEM) in vitro. Mistranslation was induced with 10µM paromomycin. Wildtype 
Firefly activity corresponds to 100’000 RLU and all measurements were done in triplicates. 
 
Untreated 
10 µM 
paromomycin Fold induction 
Codon RLU SEM RLU SEM 
K529 AGA 38 6 151 6 3.9 
K529 AGG 31 5 274 61 8.9 
K529 AAU 22 9 100 19 4.5 
K529 AAC 15 4 75 2 4.8 
K529 UUU 129 30 76 10 0.6 
H245 CAG 551 55 579 4 1.1 
H245 GAC 31 5 130 15 4.1 
H245 UAC 4376 54 3654 162 0.8 
H245 CGC 153 26 3842 448 25.1 
H245 AGA 28 0 29 2 1 
WT 100'000 --- --- --- --- 
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Fig. 18: In vitro measurements of firefly luciferase activity using different mRNA constructs. Blue bars 
represent reactions without drug and red bars represent reactions containing 10µM paromomycin. Error bars 
show SEM of triplicates and y-axis is disrupted for better view. 
5.1.2 In vitro System: Translation Inhibition 
One of the effects of aminoglycosides on translation is inhibition of protein 
synthesis. Aminoglycosides inhibit protein synthesis by blocking the translocation 
of the ribosome (Champney 2006, Borovinskaya, Shoji et al. 2008, Feldman, 
Terry et al. 2010).  
A set of eight aminoglycosides was chosen for these studies and inhibition of 
protein synthesis was measured by determining the dose-responses in vitro in 
rabbit reticulocyte lysate (RRL). Geneticin and hygromycin B showed IC50 
values of 0.3 µM and 0.1 µM, respectively. Further determined IC50 values were 
11 µM for gentamicin, 25 µM for paromomycin, 44 µM for neomycin, and 60 µM 
for apramycin. The IC50 value of tobramycin was 95 µM, that of amikacin 141 
µM, and that of kanamycin A 294 µM (see Figure 19). The modeled dose-
response curves from the experimentally measured luminescence units (RLU) 
could be fitted accurately, with squared Pearson-product-moment (R-square) 
values from 0.96 to 0.99.  
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5.1.3 In vitro System: Misreading Induction 
To study the effects of aminoglycosides on ribosomal accuracy we used the 
mutant H245CGC Fluc mRNA and analyzed the activities at various doses of 
drugs (see Figure 20). For geneticin, gentamicin and paromomycin high 
misreading levels were observed. Little to no misreading was observed for 
kanamycin A and apramycin.  
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Fig. 19: Aminoglycoside induced inhibition of translation of Fluc mRNA by RRL ribosomes in vitro. Error bars 
represent the SEM of triplicates. 
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Fig. 20: Absolute Numbers of Firefly activity in vitro. Untreated reaction mixtures were set as reference at 
100. 
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Mistranslation can be possibly masked by translation inhibition. Therefore, we 
related the experimentally measured Fluc values to translation inhibition: 
i) Definitions 
RWT = Signal of hRluc WT from Reference construct  
RMut= Signal of hRluc WT from Mistranslation construct  
FWT = Signal of hFluc WT from Reference construct  
FMut = Signal of hFluc Mut from Mistranslation construct 
 
ii) Quantity of proteins 
 hRlucx = hFlucx   
 hFlucx / hRlucx = 1 
 hFlucMut / hRlucMut = hFlucWT / hRlucWT  
 hFlucMut/hFlucWT = hRlucMut/hRlucWT  
  hRlucMut / hRlucWT = EQ  
hFlucMut = hFlucWT * EQ 
 
iii) Curves 
Inhibition = FWT (at conc. x, with 100 = value measured with no aminoglycoside) 
Mistranslation = (FMut/FWT)*(RWT/RMut) (at conc. x, with 100 = value measured 
with no aminoglycoside) 
Fold Induction = Mistranslation (conc. x) / Mistranslation (conc. 0) 
 
 
Following normalization all aminoglycosides except apramycin showed a dose-
response of misreading induction (see Figure 21). At IC50, a 15.0-fold 
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misreading induction was observed for paromomycin, followed by geneticin with 
11.4-fold at IC50. Gentamicin and amikacin showed an induction of 8.8- and 7.7-
fold, respectively. With neomycin a 4.6-fold, tobramycin a 3.6-fold and kanamycin 
A a 3.0-fold misreading induction was found. No misreading induction was 
observed for apramycin. When these experiments were performed with Fluc 
mRNA containing the non-cognate mutation H245AGA no Fluc activity was 
observed for the tested aminoglycosides. 
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Fig. 21: Fold induction of misreading in vitro at IC25 (yellow), IC50 (red), and IC75 (blue). Values were 
calculated by comparing Fluc mut/Fluc wt.  
 
5.1.4 In vivo System: Translation Inhibition 
As a next step, we studied translation inhibition in an eukaryotic in vivo model 
system. HEK293 cells were transfected with a plasmid coding for two luciferases 
fused by a 27 nucleotide linker (see Figure 22). 
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Fig. 22: Luciferase construct used for measurements of in vivo misreading experiments. The two luciferases 
renilla and firefly were fused with a 27 nucleotide linker sequence. Transcription is under control of a CMV 
promoter and the construct contains a standard poly-A signal at the 3’ end. 
 
The 5’ luciferase, Rluc, was used to control for transfection efficiency and 
translation inhibition, whilst the 3’ luciferase, Fluc containing the H245CGC 
mutation, served to measure misreading. Cells were grown in DMEM and then 
transferred to a serum free growth medium containing 15µg/ml saponine, a mild 
non-ionic detergent to permeabilize cell membranes. After 24 hours of 
incubation, cells were lysed and luciferase activities were measured.  
Dose-response curves were measured (see Figure 23). Geneticin and 
hygromycin B were the strongest translation inhibitors with IC50s of 4.6 µM and 
2.6 µM, respectively. Paromomycin had an IC50 of 249 µM followed by 
gentamicin with an IC50 of 473 µM. IC50s were 552 µM for apramycin, 769 µM 
for neomycin, 841 µM for tobramycin, and 919 µM for amikacin. Fitted curves 
showed an R-square of 0.96 to 0.99. 
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Fig. 23: Inhibition of translation in vivo by different aminoglycosides. Error bars represent the SEM of 
triplicates. 
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5.1.5 In vivo System: Misreading Induction 
We analyzed misreading induction in HEK293 cells using Fluc H245CGC 
constructs. Increasing amounts of drugs were applied and firefly activities were 
measured (see Figure 24). Geneticin showed the most pronounced absolute 
increase of misreading. As the effect on translation accuracy can be masked by 
the inhibitory effect of aminoglycosides, we normalized the measured mutant 
firefly luciferase values by relating them to the values of the renilla luciferase 
which is fused to the Fluc (see Figure 22).  
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Fig. 24 Absolute numbers of firefly activity in vivo. A) 4,5-aminoglycosides and apramycin, B) 4,6-
aminoglycosides. Untreated reaction mixtures were set as reference at 100. Error bars represent the SEM of 
triplicates. 
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When Fluc numbers were normalized to translation inhibition, four out of eight 
drugs showed an induction of misreading in vivo (see Figure 25). Geneticin was 
the most potent drug with a 4.0-fold induction of mistranslation at IC50. Other 
strong misreading inducers were amikacin (3.2 fold at IC50), paromomycin (2.8-
fold at IC50) and gentamicin with 2.2-fold at IC50. No significant misreading 
induction at IC50 was observed for apramycin, neomycin, tobramycin and 
kanamycin A. No misreading was observed when experiments were performed 
with a H245AGA construct. 
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Fig. 25: Fold induction of misreading in vivo at IC25 (yellow), IC50 (red), and IC75 (blue). For kanamycin A 
the IC75 was not in a reasonable range and therefore calculation of the induction may lead to false 
conclusions.  
 
5.1.6 Discussion 
Aminoglycosides are potent antibiotics that target the ribosome. The interaction 
of aminoglycosides with the cytosolic ribosome results in translation inhibition 
and affects the fidelity of translation. In the subset of aminoglycosides analyzed 
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here, the potency to inhibit translation of the different compounds was found to 
cover a wide range of concentrations. Experiments demonstrated IC50 over 
three orders of magnitude with hygromycin B as the most potent compound 
tested in vitro and in vivo. In general, the concentrations needed to reach IC50 
were around 10- to 20-fold lower in vitro than in vivo – reflecting the prescence of 
the cell membrane in the in vivo system. However, the results correlate well 
when comparing IC50 values of in-vitro and in-vivo experiments (see Figure 26). 
In both systems the most potent aminoglycoside tested was hygromycin B, 
closely followed by geneticin. The aminoglycosides amikacin and kanamycin A 
were in both systems the least effective compounds. 
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Fig. 26: Comparison of IC50 values in RRL versus IC50 values in HEK293 cells. Numbers on x- and y-axis 
represent the concentration of drug in µM. The accuracy of fit corresponds to an R-square (squared 
Pearson-product-moment) of 0.86 and is assumed to be significant with p<0.01.  
 
Similar to translation inhibition the induction of misreading correlates also well 
between the in vitro and the in vivo measurements (see Figure 27). Geneticin 
and paromomycin were shown to be very potent inducers of misreading. On the 
opposite apramycin, tobramycin and kanamycin A showed little or no misreading 
at IC50. 
Rabbit Ribosomes 
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Fig. 27: Comparison of fold induction of misreading in RRL versus fold induction of misreading in HEK293 
cells at IC50. The accuracy of fit corresponds to an R-square of 0.78 and is assumed to be significant with 
p<0.05.  
 
We also assessed the correlation of misreading with readthrough – the latter data 
was kindly provided by Stefan Duscha. Readthrough was measured with a 
similar assay as used for misreading. Within the linker sequence of the 5’ renilla 
luciferase and the 3’ firefly luciferase a stop codon was introduced and the 
amount of readthrough was determined. The higher values for readthrough 
measurements most likely reflect the fact that for readthrough of a premature 
stop codon virtually any amino acid can be incorporated to result in a functional 
protein. In contrast, for functional proteins in the misreading assay only the 
correct near-cognate amino acid restores the active center of the protein. As 
shown in Fig. 28 aminoglycoside-induced misreading and aminoglycoside-
induced readthrough correlate well.  
 
 
Rabbit Ribosomes 
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Fig. 28: Comparison of readthrough induction versus misreading induction in HEK293 cells at IC50. 
Numbers on x- and y-axis represent the measured luminescence. The accuracy of fit corresponds to an R-
square of 0.78 and is assumed to be significant with p<0.01.  
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5.2 Drug-Induced Mitochondrial Unfolded Protein Response 
5.2.1 Test System and Drugs used 
Misfolded proteins may lead to an unfolded protein response (UPR). Over 99% of 
the mitochondrial proteins are produced by cytosolic ribosomes. Proteins 
produced in the cytosol usually fold inside the mitochondria and are therefore 
recognized if misfolded at their destination (Pfaller, Steger et al. 1988). 
Considering the misreading potential of aminoglycosides, we set out to study 
wether aminoglycosides which induce misreading on the cytosolic ribosome 
induce a mitochondrial UPR (UPRmt). Induction of Hsp60 or ClpP can be used as 
marker of UPRmt (Zhao, Wang et al. 2002). HEK293 cells were transfected with a 
reporter plasmid containing the promoter of either Hsp60 or ClpP fused to a 
firefly luciferase gene as reporter (see Figure 29). After 24 hours, medium was 
replaced and drug was added. Cells were then incubated for another 48 hours. 
Hsp60 and ClpP expression levels were detected by measuring firefly luciferase 
activity. As internal translation control, cells were co-transfected with a plasmid 
containing β-galactosidase under control of a CMV promoter (see Figure 29).  
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Fig 29: Schematic view of the constructs used to measure UPRmt induction. A) Original constructs as 
supplied by Houtkooper et al. (Houtkooper, Mouchiroud et al. 2013) B) Constructs used to verify results 
obtained with original constructs. C) Construct to assess ClpP induction as supplied by Zhao et al. (Zhao, 
Wang et al. 2002). 
 
In this study we used the 4,6-aminoglycosides geneticin and gentamicin, the 
unique aminoglycoside hygromycin B, the glutarimide antibiotic cycloheximide, 
the tetracycline doxycycline, and linezolid which belongs to the class of 
oxazolidinones.  
When assessing the translation inhibition of the cytosolic ribosome, a dose-
response curve was observed for hygromycin B, geneticin, cycloheximide and 
gentamicin. Doxycycline and linezolid, on the other hand, did not show any 
translation inhibition of the cytosolic ribosome (see Figure 30).  
To analyze the effect of the used antibiotics on the mitochondrial ribosome, we 
performed in organello translation. With this method we monitored the 
productivity of the mito-ribosome, in particular COX1 translation. In brief, 
mitochondria from HEK293 cells were isolated and different concentrations of 
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drugs were added to reaction mixtures containing 35S-methionine. After two 
hours, reactions were stopped and samples were resolved by SDS-PAGE. 
Hygromycin B and gentamicin showed a clear dose-response on inhibiting the 
mitochondrial ribosome. In contrast, geneticin showed only little inhibition of the 
mitochondrial ribosome even up to a concentration of 1000 µM. We found also 
significant translation inhibition of the mitochondrial ribosome when we applied 
doxycycline or linezolid. No inhibition was observed when using cycloheximide 
(see Figure 31).  
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Fig. 30: Translation inhibition of the cytosolic ribosome in vivo by doxycycline, cycloheximide, linezolid, 
gentamicin, hygromycin B and geneticin.  
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Fig. 31: In organello translation of COX1. A) SDS-PAGE gel of the mtDNA encoded protein COX1. 
Gentamicin, geneticin, and cycloheximide were titrated from 0 to 1000 µM. Hygromycin B, doxycycline and 
linezolid were titrated from 0 to 100 µg/ml. B) Inhibition curve prepared from data measured from gel of 
COX1 expression. 
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5.2.2 Mito-UPR: Validation of the system 
We analyzed UPRmt by measuring the activity of a reporter gene fused to the 
promoter of the genes Hsp60 and ClpP. As translation control, a reporter gene 
fused to the constitutively active CMV promoter was used. We initially wanted to 
exclude an artifact resulting from promoter-reporter gene combination. Therefore, 
we prepared different promoter-reporter gene constructs (compare Figure 29 A 
and B). We compared the results from HEK293 cells co-transfected with two 
plasmids containing Hsp60-Fluc and CMV-lacZ with the results from HEK293 
cells co-transfected with two plasmids containing Hsp60-lacZ and CMV-Fluc. 
Cells were co-transfected for 24 hours under standard conditions and then 
medium was replaced with low-glucose DMEM containing the indicated 
concentrations of drug. After 48 hours of incubation, cells were lysed and Fluc 
and β-galactosidase activity was measured. Surprisingly, regardless of their 
target (cytosolic or mitochondrial ribosome) all ribosomal inhibitors were found to 
induce reporter activity. The resulting values for induction of UPRmt were 
between 1.7 and 2.1 for cells treated with drugs and 0.9 to 1.1 for controls (see 
Figure 32). Statistical analysis showed that there is no significant difference 
between the two constructs used for measurements (p = 0.8823).  
 
Fig. 32: Comparison of UPRmt reporter systems. Cells were treated with geneticin (600 µM), hygromycin B 
(300 µM), doxycycline (20 µg/ml) or cycloheximide (20 µM). Error bars indicate SEM of triplicates.  
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5.2.3 Mito-UPR: Dose – Response  
In a first hypothesis, we assumed that aminoglycoside induced mistranslation 
and as a consequence misfolded proteins should trigger a specific UPRmt. A 
mutant version of the mitochondrial matrix protein ornithine transcarbamylase 
(OTC) was used as positive control as established by Zhao et al. (Zhao, Wang et 
al. 2002). The Hsp60 promoter activities in cells transfected with plasmids 
containing either the wild type or mutant version of OTC were compared. The 
mutant, OTC∆, is characterized by a deletion of the phosphate binding domain 
(aminoacids 30-114) and is known to elicit UPRmt. Using various drugs in 
different concentrations, we prepared a dose-response correlation using the 
Hsp60-Fluc reporter. Dose-dependent induction of UPRmt was observed for 
doxycycline, cycloheximide, geneticin, hygromycin B and, gentamicin (see Figure 
33). As a negative control we used tunicamycin which does not interfere with 
ribosomal translation activity and did not elicit any UPRmt.  
 
Fig. 33: Hsp60 Induction in HEK293 cells grown in F10 with 15 µg/ml saponin. Concentrations are in µM for 
cycloheximide, geneticin, hygromycin B, and gentamicin, in µg/ml for doxycycline and tunicamycin. OTC: 
Ornithinetranscarbamylase. Error bars indicate SEM of triplicates. 
 
	57	
	
5.2.4 Mito-UPR: Induction of ClpP and Hsp60 
Next to the mitochondrial chaperone Hsp60, ClpP, a subunit of the mitochondrial 
AAA+ protease ClpXP, was found to be regulated in a UPRmt dependent manner 
(Aldridge, Horibe et al. 2007). Doxycycline targets the mitochondrial ribosome 
only and induced both reporter to a comparable level, i.e. 1.9-fold for Hsp60 and 
1.8-fold for ClpP. A similar result was obtained with linezolid which also targets 
the mitochondrial ribosome only with 2.1-fold for Hsp60 and 1.8-fold for ClpP. 
Hygromycin B, which targets both the cytosolic and the mitochondrial ribosome, 
induces Hsp60 3.1-fold and ClpP 2.6-fold. The highest induction of Hsp60 
showed geneticin with 4.0-fold where it induces ClpP 2.5-fold. Cycloheximide 
induced Hsp60 2.5-fold and ClpP 1.7-fold (see Figure 34). Interestingly, 
independent of the applied drug the induction of Hsp60 was always higher than 
the induction of ClpP.  
 
Fig. 34: A) Analysis of ClpP and Hsp60 induction by different drugs. Cells were grown in DMEM and 
incubated with drug for 48 hours. Concentrations of drugs were 20 µg/ml doxycycline (Dox), 20 µg/ml 
linezolid (Lin), 300 µM hygromycin B (Hyg), 600 µM geneticin (Gen), 20 µM cycloheximide (CHX). Error bars 
indicate SEM of triplicates. 
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5.2.5 Discussion 
To maintain homeostasis in mitochondria, cells possess a well regulated system 
of chaperones and proteases (Zhao, Wang et al. 2002, Haynes and Ron 2010). 
Disturbance of homeostasis leads to a mitochondria-specific unfolded protein 
response (UPRmt). This can be triggered by an imbalance of nuclear and 
mitochondrial encoded proteins, e.g. in the electron transport chain, or by an 
insufficient abundance of mitochondrial chaperones. To produce an imbalance 
we applied translation inhibitors to whole cell cultures and measured induction of 
specific UPRmt genes. In a first step we validated the inhibiting effect on the 
cytosolic ribosome. The inhibiton curves of hygromycin B and geneticin are 
nearly identical with those from the misreading experiments before (compare 
Figure 23 and Figure 30) and can therefore be used as a control to support the 
results of the inhibition of the cyto-ribosome by the other compounds. We also 
hypothesized that geneticin should elicit an UPRmt because of its mistranslation 
inducing effect. However, induction of UPRmt was observed not only for geneticin 
but for cycloheximide, which inhibits translation on a comparable level but does 
not induce any misreading. Cycloheximide should have served to estimate the 
amount of UPRmt induction by translation inhibition only. Using this method it 
would have been possible to identify the amount of UPRmt induction by misfolded 
proteins. Recent findings by Houtkooper et al. shed light on this unexpected 
result by revealing the importance of the mito-nuclear protein imbalance for 
induction of UPRmt (Houtkooper, Mouchiroud et al. 2013). Our results 
demonstrate that UPRmt is induced irrespective of where the mito-nuclear protein 
imbalance originates, i.e. UPRmt is induced whether the mito-ribosome (linezolid 
and doxycycline), the cyto-ribosome (geneticin and cycloheximide), or both types 
of ribosomes (hygromycin B and gentamicin) are affected. Apparently, translation 
inhibition of either the cytosolic or the mitochondrial translation is sufficient to 
induce UPRmt. Another finding was the clear correlation between the induction of 
Hsp60 and ClpP (see Figure 35). Both proteins are involved in UPRmt but differ 
significantly in their functional role. Hsp60 has chaperone activity while ClpP acts 
as a mitochondrial protease. A mito-nuclear protein imbalance most likely affects 
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respiratory chain formation as its subunits orginate from both, the cytosol and the 
mitochondrium (see Figure 11), e.g. incomplete and therefore non-functional 
respiratory chain complexes lead to increased reactive oxygen species (ROS) 
production (Baker, Tatsuta et al. 2011).  
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Fig. 35: Comparison of fold induction of Hsp60 versus fold induction of ClpP in HEK293 cells. The goodness 
of fit corresponds to an R-square of 0.84 and is assumed to be significant with p<0.01 
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6 MATERIAL AND METHODS 
6.1 Cell Culture 
Cell line HEK293 (Invitrogen) was used for in vivo experiments. Cells were grown 
in DMEM (Gibco) containing 10% FBS (v/v) and 4.5 g Glucose per liter in 10 cm 
petri-dishes at 37 °C and 5% CO2. When reaching 90% confluency, cells were 
split by washing 2 times with 5 ml prewarmed PBS followed by detaching with 
850 µl 0.05% Trypsin (Gibco) and resuspension in 2 ml DMEM. Cells were then 
seeded to new petri-dishes with an initial confluency of 5 – 10%. 
 
6.2 Plasmids 
6.2.1 Dual Luciferase Assay in-vitro 
Name Gene of Interest Usage 
pT7-Rluc Renilla Luciferase Internal Control 
pT7-Fluc WT Firefly Luciferase WT Internal Control 
pT7-Fluc K529AGA Mutated firefly luciferase to produce mRNA for measuring 
misreading in-vitro in rabbit reticulocyte lysate 
pT7-Fluc K529AGG 
pT7-Fluc K529AAU 
pT7-Fluc K529AAC 
pT7-Fluc K529UUU 
pT7-Fluc H245CAG 
pT7-Fluc H245GAC 
pT7-Fluc H245UAC 
pT7-Fluc H245CGC 
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pT7-Fluc H245AGA 
 
6.2.2 Dual Luciferase Assay in-vivo 
Name Gene of Interest Usage 
pRM-Rluc-Fluc Fusion of renilla luciferase 
and firefly luciferase under 
CMV promoter 
Wildtype control with internal 
standard 
pRM-Rluc-Fluc H245CGC Fusion of renilla luciferase 
and mutated firefly luciferase 
with mutation in the active 
center under CMV promoter 
Construct with near-cognate 
mutation of H245 to measure 
misreading including internal 
standard 
pRM-Rluc-Fluc H245AGA Fusion of renilla luciferase 
and mutated firefly luciferase 
with mutation in the active 
center under CMV promoter 
Construct with non-cognate 
mutation of H245 for usage as 
negative control 
 
6.2.3 UPRmt 
Name Gene of Interest Usage 
pRM-Hsp60-Fluc Firefly luciferase under control 
of the Hsp60 promoter 
Measurement of UPRmt 
induction in eukaryotic cells 
in-vivo (Source: Houtkooper, 
Mouchiroud et al., 2013) 
pRM-CMV-β-Gal β-Galactosidase under control 
of the CMV promoter 
Internal control / standard to 
normalize Hsp60 induction 
data (Source: Houtkooper, 
Mouchiroud et al., 2013) 
pRM-Hsp60- β-Gal β-Galactosidase under control Measurement of UPRmt 
induction in eukaryotic cells 
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of the CMV promoter in-vivo  
pRM-CMV-Fluc Firefly luciferase under control 
of the Hsp60 promoter 
Internal control / standard to 
normalize Hsp60 induction 
data 
pRM-ClpP-Fluc Firefly luciferase under control 
of the ClpP promoter 
Measurement of UPRmt 
induction in eukaryotic cells 
in-vivo (Source: Zhao, Wang 
et al., 2002) 
 
6.3 Dual Luciferase Assay in-vitro 
Rabbit reticulocyte lysate (RRL, Promega) was used for in vitro translation. Fluc 
mRNAs with different mutations were used in in vitro translation reactions; in 
addition Rluc mRNA was used as internal control (see 6.2.1). Firefly and renilla 
luciferase mRNAs were produced using T7 RNA polymerase (Fermentas) in vitro 
on templates of modified plasmids pGL4.14 (firefly luciferase) and pGL4.75 
(renilla luciferase) (both Promega). In these plasmids the mammalian promoter 
driving transcription of luciferases was replaced by the T7 bacteriophage 
promoter. A standard 15 μl reaction contained 10 μl RRL, 2 μg of in vitro 
transcribed reporter mRNA, 200 μM amino acid mixture, 12 Units RNasin 
(Fermentas) and serially diluted aminoglycosides. The reaction mixture was 
incubated at 37º C for 35 min. Following incubation, luciferase assay substrate 
(Promega) was added (75 μl) and luciferase activities were determined using a 
luminescence microplate reader (Bio-Tek Instruments; FLx800). 
 
6.4 Dual Luciferase Assay in-vivo 
HEK293 cells were grown to 80% confluency at 37º C in DMEM supplemented 
with 10% FBS (v/v) (Invitrogen) and subsequently transfected using TurboFect 
transfection reagent (Fermentas) and pRM Rluc-Fluc according to the 
manufacturer’s instructions. Following transfection cells were incubated for 24 
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hours. Medium was replaced by F10 (Invitrogen) w/o FBS. Serially diluted 
aminoglycoside antibiotics were added together with saponin (15 μg/ml) and cells 
were incubated for another 24 hours. Cells were lysed and luciferase activities 
were determined. Vector pRM Rluc-Fluc was constructed on the basis of vectors 
pGL4.14 and pGL4.75 (Promega). Following digestion of pGL4.14 with NheI/SalI, 
the resulting 3.6 kb fragment (Fluc with SV40 polyA signal) was inserted into 
vector pGL4.75 digested with XbaI/SalI (Rluc under control of the CMV 
promoter). The resulting 7.6 kb transitional construct pRep-00 carries two 
separate genes Rluc and Fluc. Rluc and Fluc were fused by a 27 nt linker, 
encoding the 9 amino acid polypeptide STCDQPFGF using overlap PCR 
mutagenesis resulting in vector pRM Rluc-Fluc. The Rluc activity was used as an 
internal standard.  
 
6.5 β-Galactosidase Assay 
To measure β-Galactosidase activity, an adapted version of the method 
developed by Nielsen et al. was used (Nielsen, Chou et al. 1983). Cells were 
lysed with lysis buffer from dual luciferase assay (Promega). 50 µl of cell lysate 
were mixed with 950 µl Z-Buffer (1mM MgSO4, 10 mM KCl, 50 mM β-
Mercaptoethanol, 60 mM Na2HPO4, 40 mM NaH2PO4, pH 7.5) and preincubated 
for 5 min at 37°C, followed by addition of 200 µl ONPG solution (4mg/ml o-
nitrophenolgalactosid, 60 mM Na2HPO4, 40 mM NaH2PO4, pH 7.5). This mixture 
was incubated until a detectable yellow color formed at 37°C in the dark (approx. 
2 hours). Then 300 µl 1 M Na2CO3 was added to terminate the reaction and 
absorption at 420 nm was measured in a photometer (Eppendorf). 
 
6.6 Mitochondrial in-organello Translation 
Mitochondria were isolated from HEK293 cells as described. HEK293 cells were 
collected from a 90% confluent 10-cm plate, washed with 1 X PBS and re-
suspended in 1 ml of extraction buffer (20 mM Hepes-KOH pH 7.5, 0.25 M 
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sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1mM EGTA, 1mM DTT). Cells 
were broken by passing 5 times through a syringe needle 0.45x12 mm, 
centrifuged 5 min at 800g and the supernatant transferred to a new Eppendorf 
tube. The pellet was re-suspended in 1 ml of extraction buffer, passed through a 
syringe needle 0.45x12 mm, centrifuged for 5 min at 800g, the supernatant 
collected, combined with the previous supernatant and centrifuged 15 min at 
10000g. The resulting pellet was used as mitochondria-enriched fraction. 
Mitochondrial in-organello translation was performed with slight modifications as 
described. The mitochondria-enriched pellet was re-suspended in 1ml of 
mitochondria reaction buffer containing 20 mM Tris-HCl pH 7.2, 90 mM KCl, 4 
mM MgSO4, 1.5 mM KH2PO4, 20 mM glutamate, 0.5 mM malate, 14 mM 
sucrose, 44 mM sorbitol, 1 μM methionine, 2 mM ADP, 0.1 mM amino acids (-
methionine), 1 mg/ml BSA (fatty acids free), 0.1 mg/ml cycloheximide. 15 μl of 
S35-methionine [370 MBq(10mCi)/ml, specific activity 37 TBq(1000Ci)/mmol, 
Hartmann Analytic KSM-01] were added, the suspension split into aliquots of 54 
μl and drugs added to a final reaction volume of 60 μl (compounds were 
dissolved in H2O with pH adjusted to 7.5 using 5 M KOH). Reaction mixtures 
were incubated for 2 h at 30 °C with shaking. After incubation the reaction 
mixtures were centrifuged for 5 min at 15000g, the supernatants discarded and 
pellets washed with cold washing buffer containing 10 mM Tris-HCl pH 7.4, 320 
mM sucrose, 1 mM EDTA, centrifuged 5 min at 15000g and pellets re-suspended 
in 10 μl of H2O. SDS loading buffer was added and the samples were resolved 
by 18% SDS polyacrylamide gelelectrophoresis. The gel was fixed, dried and 
exposed on a phosphoimager screen. Translation was quantified using Aida 
Image Analyzer v. 3.52 (Fuji) by scanning COX1 protein expression.  
  
	65	
	
7 REFERENCES 
Adachi, M., Y. Liu, K. Fujii, S. K. Calderwood, A. Nakai, K. Imai and Y. Shinomura (2009). 
"Oxidative stress impairs the heat stress response and delays unfolded protein recovery." 
PLoS One 4(11): e7719. 
Aeffner, F., B. Abdulrahman, J. M. Hickman-Davis, P. M. Janssen, A. Amer, D. M. Bedwell, E. J. 
Sorscher and I. C. Davis (2013). "Heterozygosity for the F508del mutation in the cystic 
fibrosis transmembrane conductance regulator anion channel attenuates influenza severity." 
J Infect Dis 208(5): 780-789. 
Ahmed, M., S. J. Muhammed, B. Kessler and A. Salehi (2010). "Mitochondrial proteome 
analysis reveals altered expression of voltage dependent anion channels in pancreatic beta-
cells exposed to high glucose." Islets 2(5): 283-292. 
Akbergenov, R. e. a. (2011). Decoding and deafness: Two sides of a coin. Ribosomes. M. V. 
Rodnina, Wintermeyer, W., Green, R.: 249-261. 
Aldridge, J. E., T. Horibe and N. J. Hoogenraad (2007). "Discovery of genes activated by the 
mitochondrial unfolded protein response (mtUPR) and cognate promoter elements." PLoS 
One 2(9): e874. 
Andre Mattman, S. S., Michelle M. Mezei, Ramona Salvarinova-Zivkovic, Majid Alfadhel, 
Yolanda Lillquist (2011). "Mitochondrial disease clinical manifestations: An overview." BCMJ 
53(4): 5. 
Araki, K. and K. Nagata (2011). "Protein folding and quality control in the ER." Cold Spring 
Harb Perspect Biol 3(11): a007526. 
Baena-Lopez, L. A., J. Alonso, J. Rodriguez and J. F. Santaren (2008). "The expression of heat 
shock protein HSP60A reveals a dynamic mitochondrial pattern in Drosophila melanogaster 
embryos." J Proteome Res 7(7): 2780-2788. 
Baker, B. M., A. M. Nargund, T. Sun and C. M. Haynes (2012). "Protective coupling of 
mitochondrial function and protein synthesis via the eIF2alpha kinase GCN-2." PLoS Genet 
8(6): e1002760. 
Baker, M. J., T. Tatsuta and T. Langer (2011). "Quality control of mitochondrial proteostasis." 
Cold Spring Harb Perspect Biol 3(7). 
Balasubramaian, R. and P. Seetharamulu (1983). "A conformational rationale for the wobble 
behaviour of the first base of the anticodon triplet in tRNA." J Theor Biol 101(1): 77-86. 
	66	
	
Ben-Shem, A., N. Garreau de Loubresse, S. Melnikov, L. Jenner, G. Yusupova and M. Yusupov 
(2011). "The structure of the eukaryotic ribosome at 3.0 A resolution." Science 334(6062): 
1524-1529. 
Benham, A. M. (2012). "The protein disulfide isomerase family: key players in health and 
disease." Antioxid Redox Signal 16(8): 781-789. 
Bernasconi, R. and M. Molinari (2011). "ERAD and ERAD tuning: disposal of cargo and of 
ERAD regulators from the mammalian ER." Curr Opin Cell Biol 23(2): 176-183. 
Blanchard, S. C., D. Fourmy, R. G. Eason and J. D. Puglisi (1998). "rRNA chemical groups 
required for aminoglycoside binding." Biochemistry 37(21): 7716-7724. 
Borovinskaya, M. A., S. Shoji, K. Fredrick and J. H. Cate (2008). "Structural basis for 
hygromycin B inhibition of protein biosynthesis." RNA 14(8): 1590-1599. 
Branchini, B. R., R. A. Magyar, M. H. Murtiashaw, S. M. Anderson and M. Zimmer (1998). 
"Site-directed mutagenesis of histidine 245 in firefly luciferase: a proposed model of the 
active site." Biochemistry 37(44): 15311-15319. 
Branchini, B. R., M. H. Murtiashaw, R. A. Magyar and S. M. Anderson (2000). "The role of 
lysine 529, a conserved residue of the acyl-adenylate-forming enzyme superfamily, in firefly 
luciferase." Biochemistry 39(18): 5433-5440. 
Cameron, J. M., T. Hurd and B. H. Robinson (2005). "Computational identification of human 
mitochondrial proteins based on homology to yeast mitochondrially targeted proteins." 
Bioinformatics 21(9): 1825-1830. 
Carriere, M., V. Vijayabaskar, D. Applefield, I. Harvey, P. Garneau, J. Lorsch, A. Lapidot and J. 
Pelletier (2002). "Inhibition of protein synthesis by aminoglycoside-arginine conjugates." RNA 
8(10): 1267-1279. 
Chakrabarti, A., A. W. Chen and J. D. Varner (2011). "A review of the mammalian unfolded 
protein response." Biotechnol Bioeng 108(12): 2777-2793. 
Champney, W. S. (2006). "The other target for ribosomal antibiotics: inhibition of bacterial 
ribosomal subunit formation." Infect Disord Drug Targets 6(4): 377-390. 
Chevallet, M., P. Lescuyer, H. Diemer, A. van Dorsselaer, E. Leize-Wagner and T. Rabilloud 
(2006). "Alterations of the mitochondrial proteome caused by the absence of mitochondrial 
DNA: A proteomic view." Electrophoresis 27(8): 1574-1583. 
	67	
	
Copeland, W. C. and M. J. Longley (2014). "Mitochondrial genome maintenance in health and 
disease." DNA Repair (Amst) 19: 190-198. 
Cornut, B. and R. C. Willson (1991). "Measurement of translational accuracy in vivo: 
missense reporting using inactive enzyme mutants." Biochimie 73(12): 1567-1572. 
Cuadrado-Tejedor, M., J. F. Cabodevilla, M. Zamarbide, T. Gomez-Isla, R. Franco and A. Perez-
Mediavilla (2013). "Age-related mitochondrial alterations without neuronal loss in the 
hippocampus of a transgenic model of Alzheimer's disease." Curr Alzheimer Res 10(4): 390-
405. 
Cyr, D. M. and D. N. Hebert (2009). "Protein quality control--linking the unfolded protein 
response to disease. Conference on 'From Unfolded Proteins in the Endoplasmic Reticulum 
to Disease'." EMBO Rep 10(11): 1206-1210. 
Dandliker, P. J., S. D. Pratt, A. M. Nilius, C. Black-Schaefer, X. Ruan, D. L. Towne, R. F. Clark, 
E. E. Englund, R. Wagner, M. Weitzberg, L. E. Chovan, R. K. Hickman, M. M. Daly, S. Kakavas, 
P. Zhong, Z. Cao, C. A. David, X. Xuei, C. G. Lerner, N. B. Soni, M. Bui, L. L. Shen, Y. Cai, P. J. 
Merta, A. Y. Saiki and B. A. Beutel (2003). "Novel antibacterial class." Antimicrob Agents 
Chemother 47(12): 3831-3839. 
Davies, J., L. Gorini and B. D. Davis (1965). "Misreading of RNA codewords induced by 
aminoglycoside antibiotics." Mol Pharmacol 1(1): 93-106. 
Davis, A. J., N. B. Sepuri, J. Holder, A. E. Johnson and R. E. Jensen (2000). "Two 
intermembrane space TIM complexes interact with different domains of Tim23p during its 
import into mitochondria." J Cell Biol 150(6): 1271-1282. 
Daviter, T., K. B. Gromadski and M. V. Rodnina (2006). "The ribosome's response to codon-
anticodon mismatches." Biochimie 88(8): 1001-1011. 
Demirci, H., F. t. Murphy, E. Murphy, S. T. Gregory, A. E. Dahlberg and G. Jogl (2013). "A 
structural basis for streptomycin-induced misreading of the genetic code." Nat Commun 4: 
1355. 
Dever, T. E. and R. Green (2012). "The elongation, termination, and recycling phases of 
translation in eukaryotes." Cold Spring Harb Perspect Biol 4(7): a013706. 
Doonan, S., E. Marra, S. Passarella, C. Saccone and E. Quagliariello (1984). "Transport of 
proteins into mitochondria." Int Rev Cytol 91: 141-186. 
	68	
	
Dudek, M., J. Romanowska, T. Witula and J. Trylska (2014). "Interactions of amikacin with the 
RNA model of the ribosomal A-site: Computational, spectroscopic and calorimetric studies." 
Biochimie. 
Duff, P. (1992). "The aminoglycosides." Obstet Gynecol Clin North Am 19(3): 511-517. 
Dutnall, R. N., S. T. Tafrov, R. Sternglanz and V. Ramakrishnan (1998). "Structure of the 
histone acetyltransferase Hat1: a paradigm for the GCN5-related N-acetyltransferase 
superfamily." Cell 94(4): 427-438. 
Edelmann, P. and J. Gallant (1977). "Mistranslation in E. coli." Cell 10(1): 131-137. 
Edelmann, P. and J. Gallant (1977). "On the translational error theory of aging." Proc Natl 
Acad Sci U S A 74(8): 3396-3398. 
Eustice, D. C. and J. M. Wilhelm (1984). "Fidelity of the eukaryotic codon-anticodon 
interaction: interference by aminoglycoside antibiotics." Biochemistry 23(7): 1462-1467. 
Fan-Minogue, H. and D. M. Bedwell (2008). "Eukaryotic ribosomal RNA determinants of 
aminoglycoside resistance and their role in translational fidelity." RNA 14(1): 148-157. 
Feldman, M. B., D. S. Terry, R. B. Altman and S. C. Blanchard (2010). "Aminoglycoside activity 
observed on single pre-translocation ribosome complexes." Nat Chem Biol 6(1): 54-62. 
Felk, S., S. Ohrt, L. Kussmaul, A. Storch and F. Gillardon (2010). "Activation of the 
mitochondrial protein quality control system and actin cytoskeletal alterations in cells 
harbouring the MELAS mitochondrial DNA mutation." J Neurol Sci 295(1-2): 46-52. 
Fernandez, M. M., E. L. Malchiodi and I. D. Algranati (2011). "Differential effects of 
paromomycin on ribosomes of Leishmania mexicana and mammalian cells." Antimicrob 
Agents Chemother 55(1): 86-93. 
Francois, B., R. J. Russell, J. B. Murray, F. Aboul-ela, B. Masquida, Q. Vicens and E. Westhof 
(2005). "Crystal structures of complexes between aminoglycosides and decoding A site 
oligonucleotides: role of the number of rings and positive charges in the specific binding 
leading to miscoding." Nucleic Acids Res 33(17): 5677-5690. 
Gast, F. U., F. Peters and A. Pingoud (1987). "The role of translocation in ribosomal accuracy. 
Translocation rates for cognate and noncognate aminoacyl- and peptidyl-tRNAs on 
Escherichia coli ribosomes." J Biol Chem 262(25): 11920-11926. 
	69	
	
Gerard, M., A. Deleersnijder, J. Demeulemeester, Z. Debyser and V. Baekelandt (2011). 
"Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration." Mol Neurobiol 
44(1): 13-27. 
Ghosh, T., N. Pandey, A. Maitra, S. K. Brahmachari and B. Pillai (2007). "A role for voltage-
dependent anion channel Vdac1 in polyglutamine-mediated neuronal cell death." PLoS One 
2(11): e1170. 
Glick, B. S., E. M. Beasley and G. Schatz (1992). "Protein sorting in mitochondria." Trends 
Biochem Sci 17(11): 453-459. 
Gordon, D. M., A. Dancis and D. Pain (2000). "Mechanisms of mitochondrial protein import." 
Essays Biochem 36: 61-73. 
Gray, M. W., G. Burger and B. F. Lang (1999). "Mitochondrial evolution." Science 283(5407): 
1476-1481. 
Gregersen, N., J. Hansen and J. Palmfeldt (2012). "Mitochondrial proteomics--a tool for the 
study of metabolic disorders." J Inherit Metab Dis 35(4): 715-726. 
Gupta, S., A. Deepti, S. Deegan, F. Lisbona, C. Hetz and A. Samali (2010). "HSP72 protects 
cells from ER stress-induced apoptosis via enhancement of IRE1alpha-XBP1 signaling 
through a physical interaction." PLoS Biol 8(7): e1000410. 
Hajek, P. and D. M. Bedwell (1994). "Characterization of the mitochondrial binding and 
import properties of purified yeast F1-ATPase beta subunit precursor. Import requires 
external ATP." J Biol Chem 269(10): 7192-7200. 
Haynes, C. M., C. J. Fiorese and Y. F. Lin (2013). "Evaluating and responding to mitochondrial 
dysfunction: the mitochondrial unfolded-protein response and beyond." Trends Cell Biol 
23(7): 311-318. 
Haynes, C. M., K. Petrova, C. Benedetti, Y. Yang and D. Ron (2007). "ClpP mediates activation 
of a mitochondrial unfolded protein response in C. elegans." Dev Cell 13(4): 467-480. 
Haynes, C. M. and D. Ron (2010). "The mitochondrial UPR - protecting organelle protein 
homeostasis." J Cell Sci 123(Pt 22): 3849-3855. 
Haynes, C. M., Y. Yang, S. P. Blais, T. A. Neubert and D. Ron (2010). "The matrix peptide 
exporter HAF-1 signals a mitochondrial UPR by activating the transcription factor ZC376.7 in 
C. elegans." Mol Cell 37(4): 529-540. 
	70	
	
Hebert, D. N. and M. Molinari (2007). "In and out of the ER: protein folding, quality control, 
degradation, and related human diseases." Physiol Rev 87(4): 1377-1408. 
Hendrick, J. P. and F. U. Hartl (1995). "The role of molecular chaperones in protein folding." 
FASEB J 9(15): 1559-1569. 
Hershko, A., A. Ciechanover and A. Varshavsky (2000). "Basic Medical Research Award. The 
ubiquitin system." Nat Med 6(10): 1073-1081. 
Hetz, C. (2012). "The unfolded protein response: controlling cell fate decisions under ER 
stress and beyond." Nat Rev Mol Cell Biol 13(2): 89-102. 
Hinnebusch, A. G. (2014). "The scanning mechanism of eukaryotic translation initiation." 
Annu Rev Biochem 83: 779-812. 
Hobbie, S. N., C. Bruell, S. Kalapala, S. Akshay, S. Schmidt, P. Pfister and E. C. Bottger 
(2006). "A genetic model to investigate drug-target interactions at the ribosomal decoding 
site." Biochimie 88(8): 1033-1043. 
Hobbie, S. N., S. K. Kalapala, S. Akshay, C. Bruell, S. Schmidt, S. Dabow, A. Vasella, P. Sander 
and E. C. Bottger (2007). "Engineering the rRNA decoding site of eukaryotic cytosolic 
ribosomes in bacteria." Nucleic Acids Res 35(18): 6086-6093. 
Hobbie, S. N., P. Pfister, C. Bruell, P. Sander, B. Francois, E. Westhof and E. C. Bottger 
(2006). "Binding of neomycin-class aminoglycoside antibiotics to mutant ribosomes with 
alterations in the A site of 16S rRNA." Antimicrob Agents Chemother 50(4): 1489-1496. 
Hoogenraad, N. J. and M. T. Ryan (2001). "Translocation of proteins into mitochondria." 
IUBMB Life 51(6): 345-350. 
Horibe, T. and N. J. Hoogenraad (2007). "The chop gene contains an element for the positive 
regulation of the mitochondrial unfolded protein response." PLoS One 2(9): e835. 
Houtkooper, R. H., L. Mouchiroud, D. Ryu, N. Moullan, E. Katsyuba, G. Knott, R. W. Williams 
and J. Auwerx (2013). "Mitonuclear protein imbalance as a conserved longevity mechanism." 
Nature 497(7450): 451-457. 
Jackson, R. J., C. U. Hellen and T. V. Pestova (2012). "Termination and post-termination 
events in eukaryotic translation." Adv Protein Chem Struct Biol 86: 45-93. 
Jacobs, A. T. and L. J. Marnett (2010). "Systems analysis of protein modification and cellular 
responses induced by electrophile stress." Acc Chem Res 43(5): 673-683. 
	71	
	
Kaldi, K. and W. Neupert (1998). "Protein translocation into mitochondria." Biofactors 8(3-4): 
221-224. 
Kampinga, H. H., J. Hageman, M. J. Vos, H. Kubota, R. M. Tanguay, E. A. Bruford, M. E. 
Cheetham, B. Chen and L. E. Hightower (2009). "Guidelines for the nomenclature of the 
human heat shock proteins." Cell Stress Chaperones 14(1): 105-111. 
Kato, H. and K. Mihara (2008). "Identification of Tom5 and Tom6 in the preprotein 
translocase complex of human mitochondrial outer membrane." Biochem Biophys Res 
Commun 369(3): 958-963. 
Kay, L., Z. Li, M. Mericskay, J. Olivares, L. Tranqui, E. Fontaine, T. Tiivel, P. Sikk, T. Kaambre, 
J. L. Samuel, L. Rappaport, Y. Usson, X. Leverve, D. Paulin and V. A. Saks (1997). "Study of 
regulation of mitochondrial respiration in vivo. An analysis of influence of ADP diffusion and 
possible role of cytoskeleton." Biochim Biophys Acta 1322(1): 41-59. 
Keeling, K. M., D. Wang, S. E. Conard and D. M. Bedwell (2012). "Suppression of premature 
termination codons as a therapeutic approach." Crit Rev Biochem Mol Biol 47(5): 444-463. 
Kondo, J., B. Francois, R. J. Russell, J. B. Murray and E. Westhof (2006). "Crystal structure of 
the bacterial ribosomal decoding site complexed with amikacin containing the gamma-
amino-alpha-hydroxybutyryl (haba) group." Biochimie 88(8): 1027-1031. 
Konstantinidis, T. C., N. Patsoukis, C. D. Georgiou and D. Synetos (2006). "Translational 
fidelity mutations in 18S rRNA affect the catalytic activity of ribosomes and the oxidative 
balance of yeast cells." Biochemistry 45(11): 3525-3533. 
Kramer, E. B. and P. J. Farabaugh (2007). "The frequency of translational misreading errors 
in E. coli is largely determined by tRNA competition." RNA 13(1): 87-96. 
Kramer, E. B. and A. K. Hopper (2013). "Retrograde transfer RNA nuclear import provides a 
new level of tRNA quality control in Saccharomyces cerevisiae." Proc Natl Acad Sci U S A 
110(52): 21042-21047. 
Kramer, E. B., H. Vallabhaneni, L. M. Mayer and P. J. Farabaugh (2010). "A comprehensive 
analysis of translational missense errors in the yeast Saccharomyces cerevisiae." RNA 16(9): 
1797-1808. 
Kumar, A., J. R. Gibbs, A. Beilina, A. Dillman, R. Kumaran, D. Trabzuni, M. Ryten, R. Walker, C. 
Smith, B. J. Traynor, J. Hardy, A. B. Singleton and M. R. Cookson (2013). "Age-associated 
	72	
	
changes in gene expression in human brain and isolated neurons." Neurobiol Aging 34(4): 
1199-1209. 
Lang, B. F., M. W. Gray and G. Burger (1999). "Mitochondrial genome evolution and the origin 
of eukaryotes." Annu Rev Genet 33: 351-397. 
Lang, B. F., E. Seif, M. W. Gray, C. J. O'Kelly and G. Burger (1999). "A comparative genomics 
approach to the evolution of eukaryotes and their mitochondria." J Eukaryot Microbiol 46(4): 
320-326. 
Laurberg, M., H. Asahara, A. Korostelev, J. Zhu, S. Trakhanov and H. F. Noller (2008). 
"Structural basis for translation termination on the 70S ribosome." Nature 454(7206): 852-
857. 
Lecca, M. R., U. Wagner, A. Patrignani, E. G. Berger and T. Hennet (2005). "Genome-wide 
analysis of the unfolded protein response in fibroblasts from congenital disorders of 
glycosylation type-I patients." FASEB J 19(2): 240-242. 
Lee, J. C. and R. R. Gutell (2012). "A comparison of the crystal structures of eukaryotic and 
bacterial SSU ribosomal RNAs reveals common structural features in the hypervariable 
regions." PLoS One 7(5): e38203. 
Lee, Y. K., D. J. Liu, J. Lu, K. Y. Chen and A. Y. Liu (2009). "Aberrant regulation and 
modification of heat shock factor 1 in senescent human diploid fibroblasts." J Cell Biochem 
106(2): 267-278. 
Lohse, M., O. Drechsel and R. Bock (2007). "OrganellarGenomeDRAW (OGDRAW): a tool for 
the easy generation of high-quality custom graphical maps of plastid and mitochondrial 
genomes." Curr Genet 52(5-6): 267-274. 
Lotz, C., A. J. Lin, C. M. Black, J. Zhang, E. Lau, N. Deng, Y. Wang, N. C. Zong, J. H. Choi, T. Xu, 
D. A. Liem, P. Korge, J. N. Weiss, H. Hermjakob, J. R. Yates, 3rd, R. Apweiler and P. Ping 
(2014). "Characterization, design, and function of the mitochondrial proteome: from organs 
to organisms." J Proteome Res 13(2): 433-446. 
Lynch, S. R. and J. D. Puglisi (2001). "Structural origins of aminoglycoside specificity for 
prokaryotic ribosomes." J Mol Biol 306(5): 1037-1058. 
Matt, T., C. L. Ng, K. Lang, S. H. Sha, R. Akbergenov, D. Shcherbakov, M. Meyer, S. Duscha, J. 
Xie, S. R. Dubbaka, D. Perez-Fernandez, A. Vasella, V. Ramakrishnan, J. Schacht and E. C. 
Bottger (2012). "Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-
	73	
	
monosubstituted 2-deoxystreptamine apramycin." Proc Natl Acad Sci U S A 109(27): 10984-
10989. 
Meisinger, C., A. Sickmann and N. Pfanner (2008). "The mitochondrial proteome: from 
inventory to function." Cell 134(1): 22-24. 
Melnikov, S., A. Ben-Shem, N. Garreau de Loubresse, L. Jenner, G. Yusupova and M. Yusupov 
(2012). "One core, two shells: bacterial and eukaryotic ribosomes." Nat Struct Mol Biol 19(6): 
560-567. 
Meyer, E. H., N. L. Taylor and A. H. Millar (2008). "Resolving and identifying protein 
components of plant mitochondrial respiratory complexes using three dimensions of gel 
electrophoresis." J Proteome Res 7(2): 786-794. 
Milon, P. and M. V. Rodnina (2012). "Kinetic control of translation initiation in bacteria." Crit 
Rev Biochem Mol Biol 47(4): 334-348. 
Mironova, L. N., N. A. Provorov, M. D. Ter-Avanesyan, S. G. Inge-Vechtomov, V. N. Smirnov and 
A. P. Surguchov (1982). "The effect of paromomycin on the expression of ribosomal 
suppressors in yeast." Curr Genet 5(2): 149-152. 
Missiakas, D., F. Schwager, J. M. Betton, C. Georgopoulos and S. Raina (1996). "Identification 
and characterization of HsIV HsIU (ClpQ ClpY) proteins involved in overall proteolysis of 
misfolded proteins in Escherichia coli." EMBO J 15(24): 6899-6909. 
Moisoi, N., K. Klupsch, V. Fedele, P. East, S. Sharma, A. Renton, H. Plun-Favreau, R. E. 
Edwards, P. Teismann, M. D. Esposti, A. D. Morrison, N. W. Wood, J. Downward and L. M. 
Martins (2009). "Mitochondrial dysfunction triggered by loss of HtrA2 results in the activation 
of a brain-specific transcriptional stress response." Cell Death Differ 16(3): 449-464. 
Nargund, A. M., M. W. Pellegrino, C. J. Fiorese, B. M. Baker and C. M. Haynes (2012). 
"Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation." Science 
337(6094): 587-590. 
Nielsen, D. A., J. Chou, A. J. MacKrell, M. J. Casadaban and D. F. Steiner (1983). "Expression 
of a preproinsulin-beta-galactosidase gene fusion in mammalian cells." Proc Natl Acad Sci U 
S A 80(17): 5198-5202. 
Ochoa, S. (1967). "Translation of the genetic message." Bull Soc Chim Biol (Paris) 49(7): 
721-737. 
	74	
	
Ogle, J. M. and V. Ramakrishnan (2005). "Structural insights into translational fidelity." Annu 
Rev Biochem 74: 129-177. 
Ortego, B. C., J. J. Whittenton, H. Li, S. C. Tu and R. C. Willson (2007). "In vivo translational 
inaccuracy in Escherichia coli: missense reporting using extremely low activity mutants of 
Vibrio harveyi luciferase." Biochemistry 46(48): 13864-13873. 
Ozawa, T., Y. Sako, M. Sato, T. Kitamura and Y. Umezawa (2003). "A genetic approach to 
identifying mitochondrial proteins." Nat Biotechnol 21(3): 287-293. 
Pagliarini, D. J., S. E. Calvo, B. Chang, S. A. Sheth, S. B. Vafai, S. E. Ong, G. A. Walford, C. 
Sugiana, A. Boneh, W. K. Chen, D. E. Hill, M. Vidal, J. G. Evans, D. R. Thorburn, S. A. Carr and 
V. K. Mootha (2008). "A mitochondrial protein compendium elucidates complex I disease 
biology." Cell 134(1): 112-123. 
Palmer, E. and J. M. Wilhelm (1978). "Mistranslation in a eucaryotic organism." Cell 13(2): 
329-334. 
Pan, Y. (2011). "Mitochondria, reactive oxygen species, and chronological aging: a message 
from yeast." Exp Gerontol 46(11): 847-852. 
Parker, J. (1989). "Errors and alternatives in reading the universal genetic code." Microbiol 
Rev 53(3): 273-298. 
Paschen, W. (2003). "Endoplasmic reticulum: a primary target in various acute disorders and 
degenerative diseases of the brain." Cell Calcium 34(4-5): 365-383. 
Pellegrino, M. W., A. M. Nargund and C. M. Haynes (2013). "Signaling the mitochondrial 
unfolded protein response." Biochim Biophys Acta 1833(2): 410-416. 
Perez-Fernandez, D., D. Shcherbakov, T. Matt, N. C. Leong, I. Kudyba, S. Duscha, H. Boukari, 
R. Patak, S. R. Dubbaka, K. Lang, M. Meyer, R. Akbergenov, P. Freihofer, S. Vaddi, P. 
Thommes, V. Ramakrishnan, A. Vasella and E. C. Bottger (2014). "4'-O-substitutions 
determine selectivity of aminoglycoside antibiotics." Nat Commun 5: 3112. 
Pestova, T. V., V. G. Kolupaeva, I. B. Lomakin, E. V. Pilipenko, I. N. Shatsky, V. I. Agol and C. U. 
Hellen (2001). "Molecular mechanisms of translation initiation in eukaryotes." Proc Natl Acad 
Sci U S A 98(13): 7029-7036. 
Pfaller, R., H. F. Steger, J. Rassow, N. Pfanner and W. Neupert (1988). "Import pathways of 
precursor proteins into mitochondria: multiple receptor sites are followed by a common 
membrane insertion site." J Cell Biol 107(6 Pt 2): 2483-2490. 
	75	
	
Pfanner, N., J. Rassow, B. Guiard, T. Sollner, F. U. Hartl and W. Neupert (1990). "Energy 
requirements for unfolding and membrane translocation of precursor proteins during import 
into mitochondria." J Biol Chem 265(27): 16324-16329. 
Pfister, P., S. Hobbie, Q. Vicens, E. C. Bottger and E. Westhof (2003). "The molecular basis for 
A-site mutations conferring aminoglycoside resistance: relationship between ribosomal 
susceptibility and X-ray crystal structures." Chembiochem 4(10): 1078-1088. 
Preuten, T., E. Cincu, J. Fuchs, R. Zoschke, K. Liere and T. Borner (2010). "Fewer genes than 
organelles: extremely low and variable gene copy numbers in mitochondria of somatic plant 
cells." Plant J 64(6): 948-959. 
Qin, D., Q. Liu, A. Devaraj and K. Fredrick (2012). "Role of helix 44 of 16S rRNA in the fidelity 
of translation initiation." RNA 18(3): 485-495. 
Raja, V. and M. L. Greenberg (2014). "The functions of cardiolipin in cellular metabolism-
potential modifiers of the Barth syndrome phenotype." Chem Phys Lipids 179: 49-56. 
Ramakrishnan, V. (1997). "Histone H1 and chromatin higher-order structure." Crit Rev 
Eukaryot Gene Expr 7(3): 215-230. 
Ramakrishnan, V., C. Davies, S. E. Gerchman, B. L. Golden, D. W. Hoffmann, T. N. Jaishree, J. 
H. Kyila, S. Porter and S. W. White (1995). "Structures of prokaryotic ribosomal proteins: 
implications for RNA binding and evolution." Biochem Cell Biol 73(11-12): 979-986. 
Ramakrishnan, V., S. Southern, N. B. Hart and K. Tzafetta (1998). "Endoscopically assisted 
gracilis harvest for use as a free and pedicled flap." Br J Plast Surg 51(8): 580-583. 
Raurell, A., S. Southern and V. Ramakrishnan (1997). "Pathological tissue expansion." Ann 
Plast Surg 39(4): 435. 
Rettig, J. (2011). Mitochondrial tRNA and protein import in Trypanosoma brucei. PhD Thesis. 
U. o. B. Faculty of Science. 
Rocha, H., R. Ferreira, J. Carvalho, R. Vitorino, C. Santa, L. Lopes, N. Gregersen, L. Vilarinho 
and F. Amado (2011). "Characterization of mitochondrial proteome in a severe case of ETF-
QO deficiency." J Proteomics 75(1): 221-228. 
Ryan, M. T., R. Wagner and N. Pfanner (2000). "The transport machinery for the import of 
preproteins across the outer mitochondrial membrane." Int J Biochem Cell Biol 32(1): 13-21. 
	76	
	
Salas-Marco, J. and D. M. Bedwell (2005). "Discrimination between defects in elongation 
fidelity and termination efficiency provides mechanistic insights into translational 
readthrough." J Mol Biol 348(4): 801-815. 
Schroder, M. and R. J. Kaufman (2005). "The mammalian unfolded protein response." Annu 
Rev Biochem 74: 739-789. 
Shao, M., B. Shan, Y. Liu, Y. Deng, C. Yan, Y. Wu, T. Mao, Y. Qiu, Y. Zhou, S. Jiang, W. Jia, J. Li, 
J. Li, L. Rui, L. Yang and Y. Liu (2014). "Hepatic IRE1alpha regulates fasting-induced 
metabolic adaptive programs through the XBP1s-PPARalpha axis signalling." Nat Commun 5: 
3528. 
Sharma, R., H. Jiang, L. Zhong, J. Tseng and A. Gow (2007). "Minimal role for activating 
transcription factor 3 in the oligodendrocyte unfolded protein response in vivo." J Neurochem 
102(5): 1703-1712. 
Sirrenberg, C., M. F. Bauer, B. Guiard, W. Neupert and M. Brunner (1996). "Import of carrier 
proteins into the mitochondrial inner membrane mediated by Tim22." Nature 384(6609): 
582-585. 
Slezak, J. A., V. W. Persky, F. J. Kviz, V. Ramakrishnan and C. Byers (1998). "Asthma 
prevalence and risk factors in selected Head Start sites in Chicago." J Asthma 35(2): 203-
212. 
Smakowska, E., M. Czarna and H. Janska (2014). "Mitochondrial ATP-dependent proteases in 
protection against accumulation of carbonylated proteins." Mitochondrion. 
Smith, S. E., S. Granell, L. Salcedo-Sicilia, G. Baldini, G. Egea, J. H. Teckman and G. Baldini 
(2011). "Activating transcription factor 6 limits intracellular accumulation of mutant alpha(1)-
antitrypsin Z and mitochondrial damage in hepatoma cells." J Biol Chem 286(48): 41563-
41577. 
Soslau, G. and J. Parker (1989). "Modulation of platelet function by extracellular adenosine 
triphosphate." Blood 74(3): 984-993. 
St John, J. (2014). "The control of mtDNA replication during differentiation and development." 
Biochim Biophys Acta 1840(4): 1345-1354. 
Szaflarski, W., O. Vesper, Y. Teraoka, B. Plitta, D. N. Wilson and K. H. Nierhaus (2008). "New 
features of the ribosome and ribosomal inhibitors: non-enzymatic recycling, misreading and 
back-translocation." J Mol Biol 380(1): 193-205. 
	77	
	
Szychowski, J., J. Kondo, O. Zahr, K. Auclair, E. Westhof, S. Hanessian and J. W. Keillor 
(2011). "Inhibition of aminoglycoside-deactivating enzymes APH(3')-IIIa and AAC(6')-Ii by 
amphiphilic paromomycin O2''-ether analogues." ChemMedChem 6(11): 1961-1966. 
Taylor, S. W., E. Fahy, B. Zhang, G. M. Glenn, D. E. Warnock, S. Wiley, A. N. Murphy, S. P. 
Gaucher, R. A. Capaldi, B. W. Gibson and S. S. Ghosh (2003). "Characterization of the human 
heart mitochondrial proteome." Nat Biotechnol 21(3): 281-286. 
Trombetta, E. S. and A. J. Parodi (2003). "Quality control and protein folding in the secretory 
pathway." Annu Rev Cell Dev Biol 19: 649-676. 
Tsai, B., Y. Ye and T. A. Rapoport (2002). "Retro-translocation of proteins from the 
endoplasmic reticulum into the cytosol." Nat Rev Mol Cell Biol 3(4): 246-255. 
Tselika, S., T. C. Konstantinidis and D. Synetos (2008). "Two nucleotide substitutions in the A-
site of yeast 18S rRNA affect translation and differentiate the interaction of ribosomes with 
aminoglycoside antibiotics." Biochimie 90(6): 908-917. 
Tuggle, K. L., S. E. Birket, X. Cui, J. Hong, J. Warren, L. Reid, A. Chambers, D. Ji, K. Gamber, K. 
K. Chu, G. Tearney, L. P. Tang, J. A. Fortenberry, M. Du, J. M. Cadillac, D. M. Bedwell, S. M. 
Rowe, E. J. Sorscher and M. V. Fanucchi (2014). "Characterization of defects in ion transport 
and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-
knockout rats." PLoS One 9(3): e91253. 
Tuite, M. F. and C. S. McLaughlin (1984). "The effects of paromomycin on the fidelity of 
translation in a yeast cell-free system." Biochim Biophys Acta 783(2): 166-170. 
Vabulas, R. M., S. Raychaudhuri, M. Hayer-Hartl and F. U. Hartl (2010). "Protein folding in the 
cytoplasm and the heat shock response." Cold Spring Harb Perspect Biol 2(12): a004390. 
Vallabhaneni, H. and P. J. Farabaugh (2009). "Accuracy modulating mutations of the 
ribosomal protein S4-S5 interface do not necessarily destabilize the rps4-rps5 protein-
protein interaction." RNA 15(6): 1100-1109. 
Verfaillie, T., N. Rubio, A. D. Garg, G. Bultynck, R. Rizzuto, J. P. Decuypere, J. Piette, C. 
Linehan, S. Gupta, A. Samali and P. Agostinis (2012). "PERK is required at the ER-
mitochondrial contact sites to convey apoptosis after ROS-based ER stress." Cell Death Differ 
19(11): 1880-1891. 
Voellmy, R. and F. Boellmann (2007). "Chaperone regulation of the heat shock protein 
response." Adv Exp Med Biol 594: 89-99. 
	78	
	
Voigts-Hoffmann, F., S. Klinge and N. Ban (2012). "Structural insights into eukaryotic 
ribosomes and the initiation of translation." Curr Opin Struct Biol 22(6): 768-777. 
Vujanac, M., A. Fenaroli and V. Zimarino (2005). "Constitutive nuclear import and stress-
regulated nucleocytoplasmic shuttling of mammalian heat-shock factor 1." Traffic 6(3): 214-
229. 
Weddle, D. O., N. S. Tu, C. J. Guzik and V. Ramakrishnan (1995). "Positive association 
between dietetics recommendations and achievement of enteral nutrition outcomes of care." 
J Am Diet Assoc 95(7): 753-758. 
Wikipedia (2007). "Mitochondrial electron transport chain—Etc4." 2014. 
Yonally, S. K. and R. A. Capaldi (2006). "The F(1)F(0) ATP synthase and mitochondrial 
respiratory chain complexes are present on the plasma membrane of an osteosarcoma cell 
line: An immunocytochemical study." Mitochondrion 6(6): 305-314. 
Yoneda, T., C. Benedetti, F. Urano, S. G. Clark, H. P. Harding and D. Ron (2004). 
"Compartment-specific perturbation of protein handling activates genes encoding 
mitochondrial chaperones." J Cell Sci 117(Pt 18): 4055-4066. 
Zaher, H. S. and R. Green (2009). "Fidelity at the molecular level: lessons from protein 
synthesis." Cell 136(4): 746-762. 
Zhao, Q., J. Wang, I. V. Levichkin, S. Stasinopoulos, M. T. Ryan and N. J. Hoogenraad (2002). 
"A mitochondrial specific stress response in mammalian cells." EMBO J 21(17): 4411-4419. 
 
  
	79	
	
8 XBP1 mitigates aminoglycoside-induced endoplasmic 
reticulum stress and neuronal cell death 
 
Naoki Oishi, Stefan Duscha, Heithem Boukari, Martin Meyer, Jing Xie, Gao Wei, 
Thomas Schrepfer, Bernd Roschitzki, Erik C. Boettger, and Jochen Schacht 
Abstract 
Here we study links between aminoglycoside-induced mistranslation, protein 
misfolding, and neuropathy. We demonstrate that aminoglycosides induce 
misreading in mammalian cells and assess ER stress and unfolded protein 
response (UPR) pathways. Genome-wide transcriptome and proteome analyses 
revealed upregulation of genes related to protein folding and degradation. 
Quantitative PCR confirmed induction of UPR markers including CHOP, GRP94, 
BiP, and XBP1 mRNA splicing, which is crucial for UPR activation. We studied 
the effect of a compromised UPR on aminoglycoside ototoxicity in 
haploinsufficient XBP1 (XBP1+/-) mice. Intra-tympanic aminoglycoside treatment 
caused high-frequency hearing loss in XBP1+/- mice but not in wild-type 
littermates. Densities of spiral ganglion cells and synaptic ribbons were 
decreased in gentamicin-treated XBP1+/- mice, while sensory cells were 
preserved. Co-injection of the chemical chaperone tauroursodeoxycholic acid 
attenuated hearing loss. These results suggest that aminoglycoside-induced ER 
stress and cell death in spiral ganglion neurons is mitigated by XBP1, masking 
aminoglycoside neurotoxicity at the organismal level. 
 
Introduction 
Translational fidelity is maintained throughout all three domains of life (archea, 
bacteria, eukaryota), suggesting a high selective pressure during evolution to 
minimize errors in protein synthesis.1 In bacteria, erroneous protein synthesis 
induces protein misfolding.2 In higher eukaryotes, protein misfolding results in 
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endoplasmatic reticulum (ER) stress and initiates the unfolded protein response 
(UPR), a cascade of integrated pathways regulating gene expression. The 
UPRER is mediated by three ubiquitously expressed transmembrane proteins in 
the ER: inositol-requiring enzyme 1 (IRE1), PKR–like ER kinase (PERK), and 
activating transcription factor 6 (ATF6).3-7 Under normal conditions, the luminal 
domains of IRE1, PERK, and ATF6 are bound by the ER chaperone binding 
immunoglobulin protein (BiP) which inhibits self-dimerization and activation of the 
cytosolic domain.8,9 Under ER stress, BiP is released resulting in dimerization of 
IRE1 and ATF6 and multimerization of PERK, initiating the UPR signaling 
cascades.8,9 The initial UPR response is protective, increasing the expression of 
chaperone proteins promoting refolding and, if unsuccessful, the degradation of 
misfolded proteins.10-13 Prolonged or severe stress triggers additional pathways 
that eventually lead to cellular apoptosis.14-16 
Aminoglycoside antibiotics are well known to affect translational fidelity in 
bacteria and lower eukaryotes17-20 but only few reports suggest that 
aminoglycoside antibiotics may also induce misreading in higher eukaryotes.21-23 
Aminoglycoside-mediated read-through activity has been exploited for therapy of 
human genetic diseases associated with premature stop codons.24-27 In addition, 
aminoglycosides have been shown to induce apoptosis in human cell cultures 
accompanied by ER stress and mitochondrial cytochrome c release.28,29 It was 
suggested that the observed ER stress may be the result of protein misfolding, 
reflecting aminoglycoside-induced mistranslation.28 Despite this potential for 
misreading induced by aminoglycosides in eukaryotes, aminoglycoside treatment 
in animal models and in patients is well tolerated. Side effects are highly organ-
specific, limited to the kidney and the inner ear,30 while toxicity to the nervous 
system is not evident even in long-term aminoglycoside treatment.31 In the case 
of ototoxicity, the primary drug target are the sensory hair cells, as convincingly 
demonstrated in various animal models, regardless of whether the drug is given 
systemically32 or directly introduced into the cochlea.33 Degeneration of spiral 
ganglion cells observed after ototoxic dosages of aminoglycosides are thought to 
occur only as a sequel to the loss of sensory hair cells in the vast majority of 
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cases. Surprisingly, however, a few analyses of human temporal bones have 
suggested that spiral ganglia can be affected by aminoglycosides without overt 
insult to the hair cells.34,35 This rare pathology, unexplained by the treatment 
modus, suggests individual variability possibly based on genetic factors. 
Prompted by the anecdotal reports of aminoglycoside-induced selective spiral 
ganglion damage, the objective of this study was to assess the contribution of ER 
stress to ototoxicity. We first investigated aminoglycoside-induced misreading 
and UPR responses in HEK293 cells in vitro. Next, we examined the role of ER 
stress in ototoxicity in cochlear organ cultures of CBA/J mice. Finally, we 
employed an in-vivo mouse model36 with a compromised ER stress response 
due to XBP1 haploinsufficiency37 in order to probe potential links between 
aminoglycoside neurotoxicity, translation fidelity and protein misfolding. 
 
Results 
Aminoglycosides alter translation fidelity. Drug-induced inhibition of 
translation was used to assess aminoglycoside activity on the eukaryotic 
ribosome. IC50 values were 0.3 μM for geneticin and 9.8 μM for gentamicin in 
the cell-free translation assays with rabbit reticulocyte lysate (RRL), and 4.4 μM 
for geneticin and 812 μM for gentamicin in assays with intact HEK293 cells 
(Supplementary Figure S1a and b). The ability of the drugs to induce 
mistranslation was analyzed using sensitive gain-of-function dual-luciferase 
assays to assess near-cognate misreading and stop-codon read-through. Near-
cognate misreading was studied using constructs with substitution of amino acid 
245 in the active site of mutated firefly luciferase (wild-type His CAC → near-
cognate Arg CGC), which results in loss of enzymatic activity with enzymatic 
function restored by misreading; stopcodon read-through was determined using 
constructs with in-frame stop codons abolishing firefly luciferase activity. Both 
geneticin and gentamicin decreased ribosomal accuracy in cell free translation 
assays (RRL) and in HEK cells in a dose-dependent manner (Figure 1). 
Misreading 
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 was induced up to 25-fold in RRL and up to 8.5-fold in HEK cells compared to 
untreated controls; read-through was induced up to 20-fold in RRL and up to 70-
fold in HEK cells compared to untreated controls (Figure 1). In HEK cells 
transfected with the aminoglycoside phosphotransferase APH(3'), the geneticin-
induced but not the gentamicin-induced translation inhibition and mistranslation 
were abrogated (Supplementary Figure S1c and d), consistent with the selectivity 
of the enzyme to inactivate geneticin but not gentamicin.38,39 Aminoglycoside-
treated and untreated HEK wild-type cells showed similar metabolic activities and 
viability (Supplementary Figure S1e and f). 
Aminoglycosides induce genome-wide upregulation of cellular folding 
capacity. In order to study the cellular response to aminoglycoside-induced 
mistranslation, we used whole genome transcriptomic and proteomic analyses. A 
microarray analysis of geneticin-treated versus untreated cells revealed a broad 
transcriptional response totaling 705 genes (selected for a fold change >1.2, 
Benjamini-Hochberg corrected p-value <0.05; Supplementary Figure S2a). 
Protein folding and transcription were among the most enriched functional 
ontologies (Supplementary Figure S2b), including the induction of the ER-specific 
chaperones BiP (HSPA5), glucose-regulated protein 94 (GRP94; HSP90B1), 
calreticulin (CALR), GRP110 (HYOU1), ERdj3 (DNAJB11), and ERdj6 
Figure 1 Aminoglycoside-induced 
mistranslation. (a–b) Misreading and 
(c–d) read-through measured in rabbit 
reticulocyte lysate (RRL; a,c) and HEK 
wild-type cells (b,d). Results are derived 
from the ratio hFluc/hRluc, given in -fold 
induction. Untreated samples are set as 
1 (n = 3; ± SEM). 
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(DNAJC3), the ER foldases PDIA3 (ERp57), PDIA4 (ERp70), Erp44, and FKBP7, 
and the N-linked glycosylation factor SDF2L1. Likewise, ER-associated 
degradation (ERAD) components such as VCP (p97), Derlin2 (DERL2), and Herp 
(HERPUD1) were significantly upregulated (Supplementary Figure S2c). This 
transcriptional response indicates a general increased folding and degradation 
capacity in the ER. In addition, a large number of cytosolic chaperones40 were 
upregulated, such as members of the Hsp40, Hsp70, Hsp90, and Hsp110 
families and to a lesser extent foldases (peptidyl-prolyl cis/trans isomerases and 
protein disulfide isomerases; Supplementary Figure S2d and e), indicating an 
increased folding capacity in the cytosol. Table S1 lists the genes included in the 
analysis. The microarray data have been deposited in NCBI's Gene Expression 
Omnibus and are accessible through GEO Series accession number GSE57198 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57198).  
 Proteome analysis found 77 proteins to be regulated by geneticin 
(Bonferroni-corrected p-value <0.05). When applying a minimum fold induction of 
0.3 (log2 scale) we identified 35 proteins that were upregulated. Grouping 
according to function revealed a predominance of proteins involved in protein 
folding (Figure 2a). Proteins associated with the ER and cytoplasmic UPR, such 
as BiP, GRP94, calreticulin, foldases, and members of the Hsp70, Hsp90, 
Hsp110, and Hsp40 families, were also upregulated (Figure 2b). Comparison 
with corresponding mRNA levels showed an upregulation of the folding 
machinery both at the transcriptomic and the proteomic level (Figure 2c). The 
mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD000933 and DOI 10.6019/PXD000933. 
	84	
	
 
 
 
 
 
Aminoglycosides induce the UPR. To corroborate the results of the microarray 
analysis, mRNA levels of selected UPR genes were further analyzed by 
quantitative PCR and corresponding protein levels were assessed by Western 
blotting. Geneticin and gentamicin induced mRNA expression of C/EBP 
homologous protein (CHOP), GRP94, and BiP in a time-dependent manner 
(Figure 3a–c). Increased protein levels of the two ER chaperones BiP and 
GRP94 as well as the transcription factor ATF4, which is regulated at the 
translational level,41 were observed in geneticin- and gentamicin-treated cells by 
Western blotting (Figure 3e). As a further element of the UPR, we studied 
Figure 2 Proteomic analysis of geneticin-treated HEK wild-type cells. (a) Thirty-five upregulated proteins were 
grouped according to their biological function (Bonferroni corrected p-value < 0.05, log2 FC > 0.3). (b) Upregulation 
of the geneticin-induced heat-shock proteins, chaperones, and foldases (Bonferroni corrected p-value < 0.05, log2 
FC > 0.3). (c) Comparison of the significantly regulated proteins (Bonferroni corrected p-value < 0.05) and their 
corresponding mRNA fold-induction. The upregulated proteins of the folding machinery are shown in red. 
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splicing of XBP1 mRNA, which is central for UPR activation11. Both geneticin and 
gentamicin induced XBP1 splicing (Figure 3d). In contrast, XBP1 splicing is 
induced neither by the non-misreading aminoglycoside hygromycin42 nor by 
cycloheximide, an inhibitor of ribosomal translocation,43 indicating that XBP1 
splicing depends on misreading and not on inhibition of translation. Furthermore, 
the presence of APH(3‘) in HEK cells abrogated geneticin-induced but not 
gentamicin-induced XBP1 splicing.  
The activity of transcription factors XBP1 and ATF6 was examined using reporter 
plasmids UPRE (p5xATF6-GL3-luc) and ERSE (pGL3-GRP78P(-132)-luc).44,45 
The UPRE reporter is specific for ATF6 activity, the ERSE reporter is regulated 
by both ATF6 and XBP1.44,45 Both reporters showed a robust induction by 
geneticin and gentamicin (Figure 3f and g). Cycloheximide failed to induce any 
reporter activity consistent with the XBP1 splicing results (Figure 3d, 3f, 3e). The 
PERK signaling branch was investigated by assessing the formation of stress 
granules, cytosolic protein aggregates composed of 48S preinitiation complexes 
and other factors. Stress granules are induced upon activation of PERK and 
phosphorylation of eIF2α.46 Treatment of HEK wild-type cells with geneticin for 
24 h increased immunostaining of p-eIF2α in a dotted cytosolic distribution 
indicative of stress granules (Figure 3h). Arsenite treatment served as a positive 
control. A similar robust induction of UPR by aminoglycosides was observed in 
Hela cells (Figure S3). 
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Gentamicin induces ER stress in spiral ganglion cells but not in auditory 
hair cells. To study the response of auditory hair cells to ER stress, we first 
employed tunicamycin, an established ER stress-inducer in early post-natal 
cochlear explants of the CBA/J mouse, a common strain for auditory research. 
Preliminary experiments (data not shown) with hair cell counts on surface 
preparations had established incubation with 0.07 μg/mL tunicamycin as a 
suitable treatment with hair cell death beginning at 48 h and progressing to 50% 
of cells by 72 h. The ER-stress-associated pro-apoptotic factor CHOP already 
appeared after 8 h of incubation with tunicamycin and was expressed in the 
nuclei of most hair cells by 24 h (Figure 4a and Supplementary Figure S4). 
Staining mostly had disappeared at 48 h (Supplementary Figure S4) when loss of 
hair cells became apparent, implicating CHOP in hair cell death. In the same 
explant model, treatment with gentamicin caused significant loss of hair cells with 
the pattern of loss showing the typical progression of aminoglycoside damage47 
with most destruction in the base (Supplementary Figure S5) while inner hair 
cells were mostly spared. Despite continuing and increasing cell death, CHOP 
was not observed throughout the entire time course up to 72 h (Figure 4a).  
Figure 3 Aminoglycosides induce the UPR. (a–c) qPCR analysis. HEK wild-type cells were treated with 
geneticin (16 μM) or gentamicin (400 μM) and incubated for the indicated times. Expression of CHOP (a), BiP 
(b), and GRP94 (c) mRNA is shown. Three biological replicates were each run in triplicate assays and means 
+ SD of fold induction relative to 0 h (untreated) sample are presented; *P<0.05; **P<0.01; ***P< 0.005; 
****P<0.001. (d) XBP1 splicing assay. HEK wild-type or HEK aph(3’) cells were treated with geneticin (16 μM), 
gentamicin (1250 μM), hygromycin (2 μM), cycloheximide (2 μM), tunicamycin (5 μg/mL) for 24 h or left 
untreated. NTC: no template control. Products of XBP1 PCR were analyzed by gel electrophoresis; unspliced 
and spliced versions of XBP1 are indicated. Tunicamycin was a positive control to induce ER stress; GAPDH 
was a loading control. The asterisk indicates the position of a hybrid amplicon (ref 15). (e) Western blot 
analysis. HEK wild-type cells were treated with geneticin (16 μM) or gentamicin (400 μM) and incubated for 24 
h. 10 μg of total protein were loaded and BiP, GRP94 and ATF4 were detected by immunoblotting using 
specific antibodies. β-actin was used as a loading control. Tunicamycin (2.5 µg/mL) was used as a positive 
control. (f-g) Reporter assays. HEK cells were transfected with luciferase reporter plasmids (f) UPRE (reporter 
for ATF6 activity) or (g) ERSE (reporter for ATF6 and XBP1 activity). Cells were treated with geneticin (16 µM) 
or gentamicin (800 µM) for 24 h. Cycloheximide (16 µM) was used as a negative control, tunicamycin (2.5 
µg/mL) was used as a positive control for UPR. Luciferase activities were determined and the Fluc/Rluc ratios 
were calculated. Untreated samples are set as 1 and fold inductions are given (n = 3-6, ± SEM). **P<0.01, 
***P<0.005. (h) Stress granule formation. HEK wild-type cells were treated with geneticin (16 μM) for 24 h or 
arsenite (0.5 mM) for 1 h as a positive control. Phosphorylated eIF2α was detected by immunofluorescence. 
Scale bars: 40 μm. The lower panels show insets in higher magnification. Bar graph indicates quantification of 
peIF2α immunofluorescence (n number of cells; nuntreated = 540; ngeneticin = 249; narsenite = 648); ****P<0.001. 
Gen: Geneticin; Gm: Gentamicin; Hyg: Hygromycin; Tm: Tunicamycin; CHX: Cycloheximide; Ars: Arsenite; Un: 
Untreated. 
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The response of ganglion neurons to ER stress was studied in spiral ganglion 
cells (SGCs) that were harvested from the base to the middle of the modiolus of 
cochlear explants and similarly treated with tunicamycin or gentamicin (Figure 
4b). As expected from its activity as an ER stressor, tunicamycin induced CHOP 
in the nuclei of SGCs within 24 h. In contrast to its effect on hair cells, gentamicin 
increased the immunoreactivity to CHOP in SGCs, evident after 48 h of 
incubation. 
 
 
 
 
 
 
 
 
Figure 4  ER stress in cochlear tissues. (a) Tunicamycin but not gentamicin causes ER stress in hair cells. 
Tunicamycin (0.07 μg/mL) induced the specific ER stress-associated pro-apoptotic factor, CHOP (green), in the 
nuclei of hair cells in organ of Corti explants by 24 h but was not observed in any part of the organ of Corti 
throughout the entire time course of gentamicin treatment (3.5 µM) until hair cell death. Segments shown are 
from the basal turn. Green: CHOP, red: Myo 7a, blue: Hoechst 33342 staining for nuclei. The figure represents 
three different explants at each time point; focal plane is the nuclear level of outer hair cells. Scale bar (Gm): 10 
μm. (b) Gentamicin induces ER stress in spiral ganglion cells (SGCs). Tunicamycin (0.07 μg/mL) treatment for 24 
h induced CHOP in the nuclei of SGCs (arrows). With gentamicin (3.5 μM) treatment, CHOP appeared in the 
nuclei of SGCs by 48 h (arrows). Green: CHOP, red: neuronal class III β-tubulin staining for SGCs, blue: Hoechst 
33342 staining for nuclei. The figure represents three different explants at each time point. Scale bar, 10 μm. 
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Gentamicin reduces spiral ganglion cells and synaptic ribbons but not hair 
cells in XBP1+/- mice in vivo. In wild-type strains such as the CBA/J mouse, the 
OHCs are the primary target of chronic aminoglycoside ototoxicity in and very 
little direct effect—if any—can be observed on SGCs. In view of the modest but 
significant gentamicin-induced CHOP expression in SGCs of cochlear explants, 
we investigated potential gentamicin-induced ER stress in a model of 
compromised UPR, an XBP1-haploinsufficient mouse. The local route of drug 
administration to the middle ear, chosen for this study, is able to isolate effects to 
the auditory periphery while avoiding adverse complications associated with 
systemic gentamicin treatment in the mouse.30  
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Preliminary experiments with a series of gentamicin concentrations starting at 
0.09 M established 0.56 M as a suitable dose that caused a moderate threshold 
shift while avoiding major pathology (data not shown).  
Surface preparations from XBP1+/- and wild-type littermates treated with 
gentamicin in vivo were examined from base to apex three weeks after drug 
injection. OHCs were present in all parts of the cochlea in both wild-type and 
XBP1+/- mice except for scattered loss at the very end of the basal turn 
(Supplementary Figure S5c). Quantitation of hair cell loss along the entire 
cochlea confirmed only minor damage at the extreme the basal turn with no 
difference between wild-type and XBP1+/- mice. 
In the absence of any discernible defects on hair cell integrity and prompted by 
the in-vitro results, we then analyzed spiral ganglion density and synaptic 
connections. Three weeks after gentamicin injection, the SGCs were counted on 
mid-modiolar cryosections stained for β-tubulin and nuclei. There was a 
significant reduction in spiral ganglion density in the basal turn of the cochlea in 
XBP1+/- mice but not in wild-type littermates (Figures 5a and 5b). The innervation 
of hair cells by the spiral ganglion was assessed by staining synaptic ribbons with 
antibody to CtBP2, a constituent of the ribbon protein RIBEYE. The number of 
synaptic ribbons per IHC was reduced by approximately 50% in the basal turn of 
Figure 5 Gentamicin reduces the number of SGCs and IHC synapses in XBP1+/- mice. Gentamicin (0.56 M) 
was locally injected into the middle ear through the bulla as described in the Methods section “Drug administration 
in vivo.” (a,b) Gentamicin reduces SGCs in XBP1+/- but not in wild-type (XBP1+/+) littermates. (a) The number of 
SGCs was counted from high-magnification images of Rosenthal’s canal of saline- and gentamicin-injected wild-
type and XBP1+/- mice. Red: neuronal class III β-tubulin staining for neural cells, blue: Hoechst 33342 staining for 
nuclei. The figure represents five different animals at each condition. Scale bar: 50 µm. (b) Quantitative evaluation 
revealed that SGC density in the basal turn of XBP1+/- mice but not in wildtype mice was significantly decreased by 
gentamicin. Filled bars, controls; open bars, gentamicin treatment. n = 5 in each group; **P<0.01. Middle and 
apical turns were not affected. (c,d) Gentamicin reduces synaptic ribbons in XBP1+/- but not in wild-type mice. (c) 
Hair cells were stained with anti-Myo7 antibodies (red) and synaptic ribbons with antibodies to CtBP2 (green). The 
number of synaptic ribbons per IHC in the basal turn was quantified from 3-D images created by using Imaris 
software. Staining of some nuclei is consistent with a partial nuclear localization of this protein,66 which has also 
been confirmed for IHCs.67 The figure represents three different animals at each condition. Scale bar: 20 µm. (d) 
Quantitative evaluation demonstrated that synaptic ribbon density of XBP1+/- mice but not of wildtype littermates 
was diminished by local injection of gentamicin. Filled bars, controls; open bars, gentamicin treatment. n = 3 in 
each group; **P<0.01 
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the cochlea of the XBP1+/- mice but not of corresponding wild-type littermates 
(Figures 5c and 5d). 
Auditory physiology corroborates auditory pathology and ER stress. In 
order to assess the impact of the observed pathology on auditory function, we 
measured auditory brain stem responses (ABR) and distortion product 
otoacoustic emissions (DPOAE). ABR provides information on the ascending 
auditory pathway reflecting synaptic and neuronal activity, while DPOAE probes 
the functional integrity of outer hair cells. Deterioration of auditory thresholds was 
apparent one week after the injection of gentamicin and remained stable for up to 
three weeks, the latest time point studied (Figure 6a). Large threshold shifts were 
observed at 32 kHz in XBP1+/- mice but not in wild-type littermates, which were 
little affected. Consistent with the morphological observations of intact outer hair 
cells, DPOAE remained unaffected by gentamicin treatment (Supplementary 
Figure S6).  
Finally, in order to validate the potential contribution of protein misfolding to the 
changes in auditory thresholds, we treated animals with TUDCA, a clinically used 
chemical chaperone. Systemic TUDCA co-administration significantly attenuated 
gentamicin-induced ototoxicity in the XBP1+/- mice (Figure 6b) as measured by 
ABR three weeks after the drug treatment. 
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Figure 6 Auditory threshold shifts 
induced by gentamicin. (a) Gentamicin 
(0.56 M) was locally injected into the middle 
ear through the bulla as described in 
‘Methods’. Three weeks after treatment, 
large threshold shifts had developed at 32 
kHz in XBP1+/- mice (square symbols) but 
not in wild-type littermates (circles). Data are 
presented as mean + SD for XBP1+/- mice 
and mean - SD for wild-types. n = 6 in each 
group; **P<0.01.  (b) TUDCA attenuates 
gentamicin ototoxicity in XBP1+/- mice. 
Animals in all three groups received the 
local injection of gentamicin and, as 
indicated, TUDCA co-treatment (500 mg/kg 
i.p. at 6 d, 3 d, and 3 h before gentamicin 
injection). Data are presented as means + 
SD of threshold shifts at 32 kHz, determined 
three weeks after treatment. n = 6 in each; 
**P<0.01 
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Discussion 
Aminoglycoside-induced loss of translational fidelity in eukaryotes is evident from 
our experiments on HEK293 cells and, moreover, is clearly linked to the 
ribosomal activity of the drugs. We have primarily chosen HEK293 cells for study 
as these cells are readily transfected, facilitating the use of reporter constructs to 
study drug-induced misreading.49 However, we have obtained similar results in 
human Hela cells. The known misreading-inducers geneticin and gentamicin, but 
not hygromycin or cycloheximide, elicit a UPR. Gentamicin was selected as a 
classical clinical aminoglycoside to bridge the findings from our in-vitro studies to 
the animal model. Geneticin was included because its inactivation by the APH(3‘) 
enzyme allowed to control for the specificity of drug action.39 Modification of 
geneticin by APH(3‘) (which abrogates its anti-ribosomal activity by 
phosphorylation of the 3‘ OH group) eliminates the ability of geneticin to cause 
both misreading and ER stress. In contrast, APH(3‘) did not affect the misreading 
activity of gentamicin, which lacks the 3‘ OH group and thus is not a target for 
APH(3‘). The finding that the cell viability and the metabolic activity of HEK wild-
type cells remain intact despite drug-induced mistranslation attests to the 
protective efficacy of cellular homeostatic responses such as the UPR and allows 
us to extrapolate that the UPR, at least in part, mitigates mistranslation induced 
by aminoglycosides in eukaryotic organisms. 
Consistent with this notion, XBP1+/- haploinsufficient mice but not wild-type mice 
sustain gentamicin-induced loss of SGCs. XBP1 is one of the central 
components in the three main pathways of the UPR, regulating molecular 
chaperones and promoting ER-associated degradation.50 The crucial function of 
XBP1 for cell survival is indicated by embryonic lethality of homozygous XBP1 
knock-out mice.37 Haploinsufficient mice are viable but are less capable of 
inducing chaperones and promoting ERAD under ER stress conditions.51 
Consequently, ER stress is prone to damage cells in XBP1+/- but not in wild-type 
mice. 
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Oxidative stress is a major factor in the pathomechanism of aminoglycoside 
ototoxicity,48 but evidence for an involvement of ER stress has been only indirect 
or lacking. Upregulation of heat shock proteins protects the mouse cochlea in 
part from aminoglycoside-induced ototoxicity in vivo.52 However, the ER stress 
marker m-calpain is unaffected by aminoglycoside treatment in the mouse 
cochlea in vivo.53 Despite the extensive loss of hair cells that gentamicin can 
cause in cochlear explants, no ER stress marker develops there. This is in 
contrast to their induction with the ER stressor tunicamycin, a finding consistent 
with previous observations of tunicamycin-induced hearing loss in the rat.54 
Further distinguishing the pathological effects of the two drugs, the damage 
caused by tunicamycin broadly encompasses all regions of the cochlea while the 
pattern of gentamicin-induced damage in the explants follows the base-to-apex 
gradient characteristic of aminoglycosides.48  
Our results clarify that aminoglycoside-induced ER stress in the cochlea is limited 
to neurons of the spiral ganglion. In the in-vivo model, the local application of a 
single low dose of gentamicin does not lead to hair cell death. However, spiral 
ganglion cells were significantly reduced in the base of the cochlea, corroborating 
the in-vitro results on ER stress in the nerve but not in hair cells. Gentamicin-
induced ER stress has also been observed in rat kidneys in vivo as part of its 
nephrotoxic actions,55 a result in agreement with our findings that 
aminoglycosides are capable of inducing ER stress in mammalian tissues. In 
accord with a gentamicin-reduced density of spiral ganglion cells, synaptic 
connections to hair cells are lost, providing an explanation for the observed high-
frequency hearing loss.  
The selective actions of gentamicin on spiral ganglion cells and synapses 
suggest a heightened sensitivity to neurodegeneration in the XBP1+/- 
haploinsufficient mice in contrast to the more common pathology of hair cell loss. 
It is interesting in this context that a loss of afferent nerve terminals and 
subsequent degeneration of the cochlear nerve has also been observed after 
moderate noise exposure that leaves the sensory cells intact.56  
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On a mechanistic level, disruption of translational fidelity causes protein 
misfolding and aggregation. The ability of XBP1 to maintain cell integrity upon 
drug-induced mistranslation appears to be mediated by induction of ER 
chaperones such as BiP, which we also find to be upregulated in response to 
aminoglycoside challenge. On an organismal level, protein misfolding has been 
associated with a variety of disorders collectively termed conformational 
diseases.57 Presumably, cell-type specific differences in the buffering capacity of 
the proteostasis network account for the cell- or organ-selectivity in some of 
these diseases.58 Aminoglycoside-induced death of hair cells has previously 
been associated with inhibition of host-cell protein synthesis47,59 and oxidative 
stress.48 The hypothesis presented here that aminoglycoside-induced loss of 
SGCs in XBP1+/- haploinsufficient mice is conferred by the drug‘s misreading 
activity is supported by the observation that administration of a chemical 
chaperone significantly alleviated the hearing loss. Specifically, we postulate that 
the UPR is normally able to maintain a protein folding equilibrium in the presence 
of aminoglycoside-induced mistranslation in SGCs. However, when the UPR 
system is compromised, e.g. by genetic haploinsufficiency of XBP1, 
aminoglycoside-induced mistranslation can manifest as neuropathology. 
 
EXPERIMENTAL PROCEDURES 
Materials and sources. Monoclonal anti-GADD 153 antibody, Santa Cruz 
Biotechnology (Dallas, TX, USA); polyclonal antibody against neuronal class III 
β-Tubulin, Covance (Princeton, NJ, USA); monoclonal anti-CtBP2 antibody, BD 
Biosciences (San Jose, CA, USA); polyclonal antibody against p-eIF2α, Cell 
Signaling (Danvers, MA, USA); polyclonal anti-myosin7a antibody (Proteus 
Biosciences, Ramona, CA, USA); secondary goat anti-rabbit antibody conjugated 
with Texas Red, Abcam (Cambridge, MA, USA); rhodamine phalloidin, Invitrogen 
(Life Technologies, Carlsbad, CA, USA); HEK293 cells, Innoprot (Biscay, Spain); 
geneticin, gentamicin, tunicamycin, cycloheximide, arsenite, saponin, and HEK 
aph(3’) cells, Sigma Aldrich (St. Louis, MO, USA); hygromycin, PAA Laboratories 
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(Cansera, Canada); nucleotide primers, Microsynth (Balgach, Switzerland); cell 
culture media and trypsin, Life Technologies (Carlsbad, CA, USA).  
Assessment of mistranslation. Misreading and stop-codon read-through were 
assessed in gain-of-function dual luciferase assays.60,61 For translation in rabbit 
reticulocyte lysates (RRL, Promega, Madison, WI, USA), luciferase mRNA was 
produced in vitro using T7 RNA polymerase (Thermo Scientific, Waltham, MA, 
USA) and plasmids pGL4.14 (firefly luciferase, hFluc) and pGL4.75 (renilla 
luciferase, hRluc; both from Promega), where the mammalian promoter was 
replaced by the T7 bacteriophage promoter. For misreading, we replaced residue 
His245 (CAC codon) with Arg245 (CGC near-cognate) in the hFluc protein by 
site-directed mutagenesis. Read-through was assessed with a fusion construct in 
which hRluc and hFluc were fused by a 27-nucleotide linker encoding the 
polypeptide STCDQPFGF, using overlap PCR mutagenesis to result in the pT7 
hRluc-hFluc vector; a UGA nonsense-codon was introduced at the glutamine 
residue (wild-type CAA) of the linker sequence by site-directed PCR 
mutagenesis. A cell-free luciferase translation assay was performed as 
described.51  Mistranslation in HEK cells was determined using the pRM hRluc-
hFluc H245R vector, where His245 (CAC codon) was replaced by Arg245 (CGC 
codon) in the pRM hRluc-hFluc vector. Read-through was determined by pRM 
hRluc-hFluc D357X, where Asp357 (GAC codon) was replaced by a UGA 
nonsense-codon in the firefly luciferase transcript. Both constructs were designed 
by site-directed PCR mutagenesis. HEK wild-type cells were transfected with 
reporter plasmid using TurboFect (Fermentas) according to the manufacturer‘s 
protocol. After a 24-h incubation, medium was replaced by F10 with 15 μg/mL 
saponin. Aminoglycoside antibiotics were added and cells were incubated for 
another 24 h. Cells were lysed and luciferase activities determined; hRluc mRNA 
was used as an internal control and misreading and read-through were quantified 
by calculating mutant firefly/renilla activities. The basal error frequency of the 
eukaryotic ribosome is 4 x 10-4 to 10-5.62 For each set of replicates, the 
hFluc/hRluc ratio of the untreated samples were set as 1, which reflects this 
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basal error frequency. Luminescence was measured in a luminometer FLx800 
(Bio-Tek Instruments, Winooski, VT). 
Viability assay. HEK cells were grown to 70% confluence and treated with 16 
µM geneticin or 400 µM gentamicin in F10 medium with 15 µg/mL saponin for the 
indicated time. Ten-percent Alamar Blue solution was added (v/v) for 3 h and 
fluorescence was monitored at 530 nm for excitation and 590 nm for emission. 
The fluorescence level of the control sample (untreated) was set as 100% after 
subtraction of background fluorescence, measured in cell-free wells. 
Sytox dead cell stain. HEK cells were grown to 60% confluence in DMEM with 
10% FBS. Medium was changed to F10 with 15 µg/mL saponin and 
aminoglycoside antibiotics were added and cells were incubated for 24 h or 48 h. 
Cells were detached by adding 100 µL accutase (Life Technologies) and were 
resuspended in 400 µL FACS buffer (1x PBS, 2% FBS) and transferred to FACS 
tubes. Sytox Red (Life Technologies) was added to the cell suspension. The 
nucleic acid stain penetrates cells with compromised plasma membranes but will 
not cross uncompromised cell membranes. The samples were then analyzed 
with a BD FACS Canto II and the FlowJo data analysis software. 
Microarray analysis. See legend to Supplemental Figure S2.  
Proteome analysis. Cell samples were incubated with lysis buffer (150 mM 
NaCl, 0.1% SDS, 0.5% Na-deoxycholate, 50 mM Tris pH 7.5, and 1× complete 
protease inhibitor (Roche)) for 10 min at RT on a shaking mixer. The lysate was 
ultrasonicated for 10 min and centrifuged for 20 min at 16,000 × g at 4 °C. Eighty 
micrograms of protein of each sample were used for iTRAQ labeling (AB SCIEX). 
Each iTRAQ 4-plex experiment was carried out with two biological replicates of 
untreated HEK wild-type cells (114 and 116 label) and two biological replicates of 
cells treated with 16 µM geneticin for 32 h (115 and 117 label) following the 
manufacturer's protocol. iTRAQ samples were pooled, dried, reconstituted in 
solvent A (5% ACN, 8 mM KH2PO4, pH 4.5), and fractionated by HILIC-HPLC 
(Pack Polyamine II, 250 × 4 mm, 120 Å S-5 µm, YMC). The column was 
equilibrated with solvent A. Peptides were eluted using solvent B (5% ACN, 100 
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mM KH2PO4, pH 4.5) by a gradient of: 0–7.5 min, 0% B; 7.5–37.5 min, 0–50% B; 
37.5–42.5 min, 50–100% B; 42.5–47.5 min, 100% B at a flow rate of 0.4 mL/min. 
The resulting 13 fractions were desalted using ZipTips (Millipore) according to 
the manufacturer’s protocol and reconstituted in solvent C (3% ACN and 0.1% 
formic acid) for LC-MS/MS analysis. Samples were auto-injected into an 
Eksigent-nano-HPLC system and separated on a custom reverse phase tip 
column (75 µm × 150 mm) packed with C18 material (3 µm, 200 Å, AQ, Bischoff 
GmbH). The column was equilibrated with solvent C and 5% solvent D (0.2% FA 
in ACN). For elution, a flow rate of 300 nL/min was used and a gradient of 0–70 
min, 5–25% D; 70–85 min, 25–50% D; 85–88 min, 50–98% D. High accuracy 
mass spectra were acquired with an AB SCIEX 5600 mass spectrometer (AB 
SCIEX) in the range of 385–1250 m/z. Up to 36 data-dependent MS/MS were 
recorded in high sensitivity mode of the most intense ions with charge states 2+, 
3+, and 4+ using collision-induced dissociation. Target ions already selected for 
MS/MS were dynamically excluded for 90 s after three occurrences. MS/MS data 
were analyzed using Mascot 2.4 (Matrix Science) and searched against a 
decoyed human database from Swissprot (release December 2012) 
concatenated with an in-house build contaminant database. The search 
parameters were: precursor ion mass tolerance of 20 ppm, fragment ion mass 
tolerance of 0.05 Da, trypsin digestion, fixed modifications of MMTS-labeled 
cysteine, 4-plex iTRAQ modifications of free amines at the N-termini and of 
lysine, and variable modification 4-plex iTRAQ of tyrosine. Peptides without 4-
plex iTRAQ labelling at the N-terminus or at a lysine were excluded from the 
analysis. Scaffold_4.1 (Proteome Software Inc., Portland, OR) was used to 
validate MS/MS-based peptide and protein identifications. We identified and 
quantified 1,785 proteins (protein prophet probability 95%, minimum two peptides 
for identification of a protein, and minimum Mascot Ionscore of 40). After the 
permutation test and further amendment of the p-value with the Bonferroni 
correction, 77 proteins were found to be regulated (p-value < 0.05). Thirty-five 
proteins were upregulated based on a threshold of 0.3 (log2-scale).  
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XBP1-splicing assay and qPCR. RNA samples from HEK cells were prepared 
using Trizol extraction (Life Technologies) and were reverse transcribed using a 
ThermoScript RT-PCR System (Life Technologies) according to the 
manufacturer‘s instructions. The XBP1 splicing assay employed XBP1-specific 
primers that amplify spliced (-26 nt) and unspliced XBP1 mRNA (forward 5‘-
TTACGAGAGAAAACTCATGGCC-3’, reverse 5’-
GGGTCCAAGTTGTCCAGAATGC-3’). PCR products were analyzed on a 2.7% 
agarose gel. Amplification of GAPDH cDNA served as loading control. For qPCR 
the Quantitect SYBR Green PCR Kit (Qiagen) was used together with the 7500 
Fast Real-Time PCR System (Applied Biosystems). The primers were CHOP: 
forward 5‘-GCGCATGAAGGAGAAAGAAC-3‘, reverse 5‘-
CCAATTGTTCATGCTTGGTG-3‘; BiP: forward 5‘-
TTTCTGCCATGGTTCTCACTAAAA-3‘, reverse 5‘-
AACATTTAGGCCAGCAATAGTTCC-3‘; GAPDH: forward 5‘-
ACCCACTCCTCCACCTTTGA-3‘, reverse 5‘-CTGTTGCTGTAGCCAAATTCGT-
3‘; GRP94 forward 5‘-TGGGAAGAGGTTCCAGAATG-3‘, reverse 5‘-
GTTGCCAGACCATCCGTACT-3‘. For relative quantification, GAPDH mRNA 
served as a reference. Measured quantification cycles were analyzed according 
to Pfaffl63, comparing treated with untreated samples. Three biological replicates 
were run in triplicates each and means and standard deviations were calculated. 
Western Blot. HEK cells were grown to 60% confluence in DMEM with 10% 
FBS. Medium was changed to F10 with 15 µg/mL saponin and aminoglycoside 
antibiotics were added and cells were incubated for 24 h. Cells were lysed in 
hypotonic buffer (20 mM HEPES pH 7.5, 10 mM KCl, 3 mM Mg Acetate, 1 mM 
DTT and 10 µg/ml DNase I) and ultrasonicated. Lysates were centrifuged 
(13.000 rpm, 10 min) and protein concentration in the supernatant was measured 
by the Micro BCA Protein Assay Kit (Thermo). Ten µg of total protein were 
resolved on 10% SDS-polyacrylamide gels and blotted on nitrocellulose 
membranes, which were probed with specific antibodies. Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare, RPN2232) was used as a 
substrate for the horseradish peroxidase (HRP). The specific antibodies used in 
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this study were: anti-BiP antibody (Abcam, ab21685); anti-GRP94 antibody 
(Abcam, ab87886); anti-ATF4 antibody (Abcam, ab23760); anti-β-actin antibody 
(Sigma, A1978-200UL); HRP-conjugated goat anti-rabbit (Invitrogen, G-21234) 
and goat anti-mouse antibodies (Invitrogen, A10551). 
UPR reporter assay. Reporter plasmids UPRE (p5xATF6-GL3) and ERSE 
(pGL3-GRP78P(-132)-luc) carrying luciferase under the control of UPR-specific 
cis-acting elements were kind gifts from Kazutoshi Mori (Kyoto University, 
Japan). HEK cells were grown to 60% confluence and co-transfected with 
reporter constructs and pGL4.75 (Rluc) using TurboFect reagent (Fermentas) 
according to the manufacturer’s protocol. After a 24-h incubation medium was 
replaced by F10 with 15 µg/mL saponin. Aminoglycosides were added and cells 
were incubated for another 24 h. Cells were lysed and luciferase activities 
determined. Normalization of luciferase activities was performed as described 
above. Cycloheximide was used as a mistranslation negative control and 
tunicamycin was used as a positive control for UPR. 
P-eIF2α immunofluorescence assay. HEK cells grown on poly-D-lysine 
(Sigma)-coated cover slips (Thermo Scientific) were treated for 24 h with 
geneticin in F10 medium with 15 µg/mL saponin, or with arsenite for 1 h (positive 
control). Cells were then fixed with 4% paraformaldehyde and methanol and 
incubated with blocking solution (1× PBS with 1% BSA and 0.5% saponin) for 1 h 
at RT. Immunostaining used a rabbit polyclonal antibody against p-eIF2α (1:250) 
and a secondary goat anti-rabbit antibody conjugated with Texas Red (1:250) 
diluted in blocking solution. Cover slips were mounted on glass slides (VWR) 
using Dapi fluoromount (Southern Biotech), and cells were imaged using a Lyca 
Sp2 confocal microscope and a 63× objective. p-eIF2α and nuclear signals were 
quantified using Imaris software (Bitplane) and the dots-per-cell ratio was 
calculated.  
Animals. Male and female CBA/J mice were purchased from Harlan Sprague-
Dawley Co. 
(http://www.harlan.com/products_and_services/research_models_and_services/r
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esearch_models/cbaj_inbred_mice.hl) at an age of 6–8 weeks and bred in-house 
in order to obtain pups for organotypic cultures of the post-natal organ of Corti 
and SGCs (see next section). XBP1+/- mice, originally derived from D3 embryonic 
stem cells, were from a stock kindly provided by Dr. Laurie H. Glimcher31 and 
received via Dr. Randal J. Kaufman, University of Michigan. Littermates served 
as wild-type (XBP1+/+) controls. Animals were kept on a 12-h light/12-h dark cycle 
with free access to water and diet (Purina 5001) and used in the in-vivo studies 
at an age of 3–4 months. Experimental protocols were approved by the 
University of Michigan Committee on the Use and Care of Animals and animal 
care was under the supervision of the University of Michigan’s Unit for Laboratory 
Animal Medicine. 
Organotypic cultures of post-natal organ of Corti and spiral ganglion cells. 
The procedures were as described previously.64 Mice at post-natal day 2–3 (p2–
3) were euthanized and cochleae dissected in cold Hank’s Balanced Salt 
Solution to isolate the organ of Corti; spiral ganglion cells (SGCs) were dissected 
from the base to the middle of the modiolus. Explants were placed onto a culture 
dish in 2 mL of medium consisting of Basal Medium Eagle, 1% serum-free 
supplement (Gibco #51500-056, Life Technologies), 1% bovine serum albumin, 5 
mg/mL glucose and 10 U/mL penicillin G, allowed to settle for 4 h (37 °C, 5% 
CO2) and incubated for 2 d to mitigate dissection stress. Medium was then 
exchanged for new media with or without drugs and incubation continued. For 
immunofluorescent labeling, explants were fixed with 4% paraformaldehyde 
overnight at 4 °C and permeabilized for 30 min with 3% Triton X-100 in 
phosphate buffered saline (PBS) at room temperature. After three washes with 
PBS and blocking with 10% goat serum for 30 min at RT, incubation with the 
primary antibodies followed at 4 °C for 72 h. After three washes with PBS, 
secondary antibodies were applied (Alexa Fluor 488-conjugated goat anti-mouse 
and Alexa Fluor 546-conjugated goat anti-rabbit antibody; 1:200 in PBS) at 4 °C 
overnight in darkness. After several rinses, specimens were mounted on a slide 
with Prolong Gold anti-fade reagent (Life Technologies) and imaged with an 
Olympus Fluoview Confocal Laser Scanning Microscope-FV500 (Olympus 
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America, Center Valley, PA). For staining of hair cells, specimens were incubated 
at RT with rhodamine phalloidin (1:100) for 1 h; or for staining of nuclei with 
Hoechst 33342 (2 µg/mL in PBS) for 40 min. Presence or absence of OHCs and 
IHCs was determined on a Leitz Orthoplan microscope (Leica, Wetzlar, 
Germany) whose right objective had a 0.19-mm scale imposed on the field. 
Successive 0.19-mm fields were evaluated beginning at the apex by observers 
blinded to the experimental conditions. Cell counts were compared to a 
normative database (KHRI Cytocochleogram, version 3.0.6, Kresge Hearing 
Research Institute, University of Michigan, Ann Arbor, MI, USA).  
Drug administration in vivo. Gentamicin was locally delivered as previously 
described.65 Mice were anesthetized with an intra-peritoneal injection of xylazine 
(7 mg/kg) and ketamine (90 mg/kg) and body temperature was maintained. The 
temporal bone was approached via a retro-auricular incision and a small hole 
was made in the thin part of the bulla with a 30-G needle. Surgical tubing was 
inserted through the hole, and 10 μL of 0.56 M gentamicin dissolved in saline 
was slowly injected. The skin incision was closed with tissue adhesive. TUDCA 
(Calbiochem, EMD Millipore, Billerica, MA, USA) was dissolved in 0.15 M 
NaHCO3 (adjusted to pH 7.4) and injected subcutaneously at 500 mg/kg body 
weight 6 d, 3 d, and 3 h before gentamicin administration. Injections of 0.15 M 
NaHCO3 served as vehicle controls. Injection of TUDCA did not cause any 
apparent side effects. 
Hair cell counts in adult mice. Three weeks after injections, cochleae were 
fixed as described above. The apical bony capsule was removed and the cochlea 
decalcified in 4% sodium EDTA (adjusted to pH 7.4) for 7 d at 4 °C. 
Subsequently, cochleae were dissected into apical, middle, and basal segments. 
Segments were permeabilized in 3% Triton X-100 for 30 min at room 
temperature, washed three times with PBS, and incubated with rhodamine 
phalloidin (1:100) at room temperature for 1 h. The procedures for cell counting 
were the same as for explants.  
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Quantification of spiral ganglion cells and synaptic ribbons. Following 
decalcification with 4% EDTA, cochleae were cryo-sectioned. Sections of 8 µm 
thickness were incubated in 0.3% Triton X-100 in PBS for 30 min at room 
temperature, blocked with 10% goat serum for 30 min, followed by incubation 
with anti-neuronal class III β-Tubulin antibody (1:2,000) for 48 h at 4 °C. After 
three rinses in PBS, sections were incubated with a secondary antibody (Alexa 
Fluor 546-conjugated; 1:500) at 4 °C overnight in darkness. After three washes 
with PBS, sections were stained with Hoechst 33342 (2 µg/mL in PBS) for 40 min 
at room temperature. After a final wash, the slides were mounted with Prolong 
Gold anti-fade reagent. Controls were processed without primary antibody. The 
number of SGCs in Rosenthal’s canal was quantified using ImageJ software 
(National Institutes of Health, Bethesda, MD) by counting the β-tubulin- and 
Hoechst-positive cells on images taken with an Olympus laser confocal 
microscope. Two mid-modiolar sections, separated by 40 to 50 μm, were used to 
obtain the average for each animal. For synaptic ribbon counts, cryo-sections 
were incubated for 30 min at room temperature with 5% donkey serum in PBS 
with 0.3% Triton X-100 and overnight in darkness at 4 °C with antibodies against 
CtBP2 (1:200) and Myo7a (1:200). After three washes in PBS (15 min each), 
tissues were incubated with secondary antibodies (Alexa Fluor 488- and Alexa 
Fluor 546-conjugated; 1:1,000) at room temperature for 1 h. After three washes, 
the epithelia were mounted and images taken on an Olympus laser confocal 
microscope. Images were reconstructed 3-dimensionally using Imaris software 
(Bitplane). The number of synaptic ribbons was quantified per IHC based on an 
average of 14 IHCs per sample.  
Auditory function measurements. For auditory brainstem responses (ABR), 
animals were anesthetized with an intra-peritoneal injection of xylazine (7 mg/kg), 
ketamine (65 mg/kg), and acepromazine (2 mg/kg), and placed in a sound-
isolated and electrically shielded booth (Acoustic Systems, Austin, TX, USA). 
Body temperature was maintained near 37 °C with a heating pad. Acoustic 
stimuli were delivered monaurally to a Beyer earphone attached to a speculum 
inserted into the left ear canal. Sub-dermal electrodes were inserted at the vertex 
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of the skull, under the left ear, and under the right ear (ground). ABRs were 
measured at 12 kHz and 32 kHz using Tucker Davis Technology (TDT) System 
III hardware and SigGen/Biosig software to present the stimuli (15 ms tone 
bursts, 1 ms rise-fall time) and record up to 1024 responses for each stimulus 
level. Thresholds were determined by reducing the intensity in 10-dB increments 
and then in 5-dB steps until no organized responses were detected. Threshold 
shifts were calculated for individual animals as the difference in auditory 
thresholds between ABR measurements before and at the end of the studies. For 
the DPOAE procedure, see the legend to Supplementary Figure S6. 
Statistical analysis. Data were evaluated by one-way ANOVA followed by 
Tukey’s Honestly Significant Difference tests using JMP version 8.0.1 (SAS 
Institute Inc.) or Student’s t-test. All tests were two-sided with significance set at 
P<0.05.  
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Supplementary Information 
 
 
Figure S1 Translation and viability assays. (a–c) Aminoglycoside-induced translation inhibition in (a) 
Rabbit reticulocyte lysate (RRL), (b) HEK wild-type cells, (c) HEK wild-type versus HEK aph(3’) cells. 
Translation inhibition is measured by hRluc activity; hRluc signals of untreated samples are set as 100% 
luciferase activity. (d) Read-through, measured in HEK wild-type versus HEK aph(3’) cells, indicated by the 
ratio hFluc/hRluc and given as fold induction. Untreated samples are set as 1. (e) Metabolic activity assay. 
HEK wild-type cells were treated with geneticin (16 µM) or gentamicin (400 µM). The Alamar Blue 
fluorescence level of the untreated samples average was set as 100%. No statistical difference was 
observed between treated and untreated controls. (f) Sytox Dead cell stain. HEK wild-type cells were treated 
with geneticin (16 µM) or gentamicin (400 µM), stained with Sytox Red and analyzed by FACS. Antimycin 
(20 µg/mL for 8 h) was used as positive control for cell death. The fluorescence level of the untreated 
samples average was set as 100% and percentage of living cells are presented. Treatment with geneticin 
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and gentamicin slightly decreased cell viability by 5-15% (p<0.05) (a,b,e,f) Data are presented as means + 
SEM (n = 3). Gen: Genteicin; Gm: Gentamicin; Ant: Antimycin; Un: Untreated. 
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Figure S2 Transcriptome analysis of geneticin-treated HEK wild-type cells (a) A comparison of 
microarray analyses of four geneticin-treated biological replicates against four untreated biological replicates 
revealed 705 genes induced by geneticin (Benjamini-Hochberg corrected p-value < 0.05, FC > 1.2). The 
figure represents a heat map of the genes. (b) Functional ontology enrichment analysis indicating the most 
significantly enriched networks (p-value < 0.0001) of the 705 up-regulated genes. (c, d, e) mRNA fold 
induction of  individual ER folding machinery and ERAD components(c), chaperones of the Hsp70, Hsp90, 
Hsp110, and Hsp40 protein families (d), and foldases (e) (Benjamini-Hochberg corrected p-value < 0.05). 
 
Methods HEK cells were treated with 16 µM geneticin in F10 medium with 15 ug/mL saponin at 37 °C for 32 
h. RNA was extracted from four independent samples for each condition (geneticin-treated, untreated). 
Biotinylated single-strand cDNA targets were prepared from 200 ng of total RNA, using the Ambion WT 
Expression Kit and the Affymetrix GeneChip WT Terminal Labeling Kit according to the manufacturer’s 
protocols. Following fragmentation and end-labeling, 1.9 μg of cDNAs were hybridized for 16 h at 45 °C on 
GeneChip Human Gene 1.0 ST arrays (Affymetrix) interrogating 28,869 genes represented by 
approximately 27 probes spread across the full length of the gene. The chips were washed and stained in 
the GeneChip Fluidics Station 450 (Affymetrix) and scanned with the GeneChip® Scanner 3000 7G 
(Affymetrix) at a resolution of 0.7 µm. Raw data (.CEL intensity files) were extracted from the scanned 
images using the Affymetrix GeneChip Command Console, version 3.2. CEL files were further processed 
with Affymetrix Expression Console software version 1.1 to calculate probe set signal intensities using 
Robust Multi-array Average algorithms with default settings. Hierarchical clustering was performed using 
Cluster and TreeView software (http://www-microarrays.u-strasbg.fr). Functional ontology enrichment of 
process networks was analysed with the MetaCore software (GeneGo, Thomson Reuters). Significance of 
the difference in expression of each gene between treated and untreated samples was tested using the 
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TREAT method and the correction of Benjamini-Hochberg for multiple testing was applied in order to take 
into account the number of tests performed. Corrected p-values < 0.05 were considered as significant.  
 
 
Figure S3 Aminoglycoside-induced UPR in Hela cells. (a–d) qPCR analysis. Hela wild-type cells were 
treated with geneticin (16 μM) or gentamicin (400 μM) and incubated for 24 h. Expression of CHOP (a), BiP 
(b), and GRP94 (c) mRNA is shown. (d) Tunicamycin was use as positive control. Experiments were run in 
triplicates and means + SD of fold induction relative to untreated samples are presented; ***P< 0.005; 
****P<0.001. (e) Stress granule formation. Hela wild-type cells were treated with geneticin (16 μM) or 
gentamicin (400 μ M) for 24 h. Phosphorylated eIF2α was detected by immunofluorescence. Scale bars: 20 
μm. Two representative pictures shown for each sample. (f) XBP1 splicing assay. Hela wild-type cells were 
treated with geneticin (16 μM) or gentamicin (400 μM) for 24 h, or left untreated. Products of XBP1 PCR 
were analyzed by gel electrophoresis; unspliced (uXBP1) and spliced (sXBP1) versions of XBP1 are 
indicated. Tunicamycin ( 2.5 μg/mL) was a positive control to induce ER stress; GAPDH was a loading 
control. The asterisk indicates the position of a hybrid amplicon (ref 15). Gen: Geneticin; Gm: Gentamicin; 
Tm: Tunicamycin; UN: Untreated. 
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Figure S4 Effect of tunicamycin on cochlear explants: Control: The specific ER stress-associated pro-
apoptotic factor, CHOP (green) is absent from untreated organ of Corti explants of CBA/J mice (P2–3). 24 h: 
After a 24-h incubation, tunicamycin (0.07 μg/mL) induced CHOP in the nuclei of most hair cells from base 
to apex of the organ of Corti. 48 h: Loss of staining consistent with beginning hair cell death. Green: CHOP, 
red: Myo 7a stain for hair cells, blue: Hoechst 33342 staining for nuclei. The figure represents three different 
explants at each time point. Scale bar: 50 μm. 
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Figure S5 Effect of gentamicin on hair cells in vitro and in vivo: a, b: Effect of gentamicin on hair cells 
in cochlear explants. (a) Loss of OHCs due to gentamicin treatment (3.5 μM for 72 h) showed the typical 
base-to-apex gradient with most destruction in the base. The figure represents six different explants from 
CBA/J mice. (b) Complete quantification of hair cell loss from apex to base of the explant. Data are mean + 
SD. Red: rhodamine phalloidin to outline hair cell structure. Scale bar: 50 μm. 
c: Effect of intratympanic application of gentamicin.  Surface preparations from adult wild-type and XBP1+/- 
mice previously treated with intratympanically applied gentamicin were examined from base to apex. Actin 
staining (red) showed the presence of OHC cuticular plates and stereocilia in all parts of the cochlea, except 
for minor scattered loss at the base. Five wildtype and five XBP1+/- mice were treated with gentamicin; the 
images are representative samples. Scale bar: 10 µm. 
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Figure S6 Distortion product otoacoustic emissions (DPOAE) remain unaltered by intratympanic 
gentamicin treatment. Animals were anesthetized with ketamine 65 mg/kg, xylazine 3.5 mg/kg, and 
acepromazine 2 mg/kg and body temperature was maintained. The primary tones, F1 and F2, were set at a 
F2/F1 ratio of 1.2. The intensity of F1 (L1) was varied in 5- or 10-dB steps (with the intensity of F1 ranging 
from 10–80 dB SPL), and the intensity of F2 (L2) was maintained 10 dB lower than L1. DPOAE were 
measured at 2F1 - F2. Tones were presented via two EC1 drivers (TDT) connected through an electret 
condenser microphone (Knowles Acoustics, type FG-23329-P07). TDT System III hardware and 
SigGen/BioSig software were used to present the stimuli and record responses. DPOAE responses in four 
adult XBP1+/- mice were measured before and after gentamicin treatment.  Lines for the four animals are 
distinguished by different symbols. 
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Supplementary Table 1. 
List of analyzed UPR and ER folding machinery genes and human chaperones and foldases. 
* Genes considered significantly regulated (p-value ≤ BH correction) 
Gene symbol Other symbols Fold change P-value BH correction 
          
UPR(Lecca, Wagner et al. 2005, Sharma, Jiang et al. 2007, Hetz 2012) 
UPR sensors         
ERN1 IRE1 0.88 0.193 0.013 
EIF2AK3 PERK 1.26 0.033 0.006 
ATF6   1.03 0.778 0.034
ATF6B   0.68 0.001* 0.001 
        
UPR Transcription factors     
ATF3   0.99 0.898 0.041 
ATF4   0.82 0.013 0.004 
ATF6   1.03 0.778 0.034 
ATF6B   0.68 0.001* 0.001 
XBP1   1.30 0.012 0.004 
DDIT3 CHOP 1.51 0.020 0.005 
          
ERAD(Araki and Nagata 2011) 
Processing and targeting     
EDEM1   0.97 0.913 0.042 
EDEM2   1.04 0.806 0.036 
EDEM3   1.12 0.182 0.012 
PDIA2 PDI, PDIP, PDIR 0.91 0.458 0.022 
HSPA5 BiP, GRP78 2.62 <0.001* <0.001 
HSP90B1 GRP94 1.49 <0.001* <0.001 
DNAJB9 ERdj4, MDG1 1.78 0.003 0.002 
DNAJC10 ERdj5, JPD1 0.82 0.015 0.004 
FOXRED2 ERFAD 0.74 <0.001* <0.001 
PPIB CyclophilinB, CYPB 1.00 0.987 0.049 
OS9  ERLEC2 0.96 0.724 0.032 
ERLEC1 XTP3-B 1.21 0.037 0.006 
SEL1L 1.25 0.061 0.007 
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Possible retrotranslocation channel     
SEC61A1 SEC61 1.03 0.845 0.038 
SEC61A2 1.13 0.300 0.017 
SEC61B 1.14 0.141 0.011 
SEC61G 1.57 0.001* 0.001 
DERL1 Derlin 1 1.08 0.458 0.022 
DERL2 Derlin 2 1.48 <0.001* <0.001 
DERL3 Derlin 3 1.43 0.008 0.003 
          
Other possible component or regulator     
HERPUD1 HERP, Mif1, SUP 2.10 <0.001* <0.001 
VIMP SELS 1.43 0.004 0.002 
BCAP31 BAP31 1.09 0.442 0.021 
JKAMP HSPC213, JAMP 1.20 0.011 0.004 
DNAJB12 DJ10 0.99 0.961 0.046 
HM13 SPP 0.99 0.949 0.045 
SSR1 TRAP alpha 0.87 0.114 0.010 
SSR2 TRAP beta 1.00 0.984 0.049 
SSR3 TRAP gamma 0.97 0.828 0.037 
SSR4 TRAP delta 0.88 0.176 0.012 
TICAM2 TRAM 1.17 0.082 0.008 
AUP1 1.22 0.002 0.002 
SVIP 1.15 0.212 0.013 
          
E2 ubiquitin-conjugating enzyme      
UBE2K UBC1, HIP2 1.20 0.008 0.003 
UBE2D1 UBCH5 1.42 <0.001* <0.001 
UBE2J1 UBC6 0.96 0.725 0.032 
UBE2J2 1.14 0.154 0.011 
UBE2G1 UBC7 1.04 0.788 0.035 
UBE2G2 1.17 0.090 0.009 
UBE2N UBC13 1.11 0.233 0.014 
          
E3 ubiquitin-ligase      
NEDD4L NEDD4-2 1.15 0.135 0.011 
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PARK2 PDJ 0.67 0.001* 0.001 
RNF5 RMA1 1.34 0.001* 0.001 
AMFR RNF45, GP78 0.95 0.638 0.028 
SYVN1 HRD1, DER3 1.28 0.007 0.003 
MARCH6 TEB4, DOA10 0.96 0.772 0.034 
RNF139 HRCA1, TRC8 1.27 0.006 0.003 
TRIM13 CAR, RNF77 1.01 0.971 0.047 
RNF103 KF1 1.09 0.343 0.018 
RNF19A RNF19 1.12 0.212 0.013 
RNF121 1.36 0.003 0.002 
STUB1 CHIP 0.95 0.679 0.030
          
SKP1-CUL1-F-box (SCF) E3      
SKP1 OCP 1.36 0.006 0.003 
CUL1 cullin-1 1.23 0.004 0.002 
FBXO2 FBG1 0.88 0.160 0.011 
FBXO6 FBG2 0.91 0.247 0.015 
RBX1 RNF75, ROC1 1.09 0.357 0.018 
          
E4 ubiquitin-conjugating enzyme      
UBE4B UFD2 0.90 0.240 0.014 
          
Substrate extraction and recruiting      
VCP p97, ALS14 1.31 0.001* 0.002 
UFD1L UFD1 1.30 0.003 0.002 
NPLOC4 NPL4 1.13 0.187 0.012 
          
UBXD family protein      
UBXN6 UBXD1 1.02 0.905 0.042 
UBXN4 UBXD2 1.12 0.226 0.014 
UBXN7 UBXD7 1.31 0.010 0.003 
FAF2 UBXD8 1.47 <0.001* 0.001 
UBXN1 UBXD10 1.02 0.844 0.038 
          
Deglycosylating enzyme      
NGLY1 PNGase 1.11 0.270 0.015 
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DUB (deubiquitination)      
VCPIP1 DUBA3, VCIP135 1.21 0.011 0.004 
YOD1 DUBA8, YOD1 1.57 <0.001* <0.001 
ATXN3 Ataxin-3 1.12 0.259 0.015 
USP19 1.19 0.071 0.008 
          
Shuttle protein         
UBQLN1 Ubiquilin1 1.18 0.017 0.004 
RAD23A HR23A 0.78 0.004 0.003 
RAD23B HR23B 0.91 0.382 0.019 
          
Ubiquitin receptor      
PSMD4 Rpn10 0.86 0.159 0.011 
PSMC3 Rpt5 0.95 0.686 0.030 
ADRM1 Rpn13 1.13 0.247 0.015 
  
 
 
        
ER Chaperones(Lecca, Wagner et al. 2005, Hebert and Molinari 2007, Araki and Nagata 2011) 
DNAJC1 ERdj1, MTJ1 0.97 0.834 0.037 
SEC63 ERdj2, DNAJC23 0.91 0.343 0.018 
DNAJB11 ERdj3, HEDJ, ERj3 2.21 <0.001* <0.001 
DNAJB9 ERdj4, MDG1 1.78 0.003 0.002 
DNAJC10 ERdj5, JPD1 0.82 0.015 0.004 
TOR1A Torsin A 1.05 0.636 0.028 
SIL1 BAP, ULG5 1.02 0.886 0.040 
HYOU1 GRP170 1.79 <0.001* 0.001 
HSP90B1 GRP94 1.49 <0.001* <0.001 
HSPA5 BiP 2.62 <0.001* <0.001 
CALR Calreticulin 1.50 <0.001* 0.001 
CANX Calnexin 1.10 0.310 0.017 
SERPINH1 HSP47 1.24 0.024 0.005 
LRPAP1 RAP 1.07 0.558 0.025 
LEPRE1 P3H1 0.95 0.641 0.028 
P4HB P4H, ERP59, PDIA1 0.95 0.668 0.029 
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DNAJC3 ERdj6 2.21 <0.001* <0.001 
          
ER foldases(Lecca, Wagner et al. 2005, Schroder and Kaufman 2005, Hebert and Molinari 2007, 
Bernasconi and Molinari 2011) 
PDIA3  ERP57, ERP61, ERP60 1.36 0.001* 0.002 
PDIA4 ERP70, ERP72 2.55 <0.001* <0.001 
DNAJC10 ERdj5 0.82 0.015 0.004 
PDIA5 PDIR 0.97 0.832 0.037 
MUTED ERP46, PDIA15 0.98 0.903 0.042 
PDIA2 PDI, PDIp, PDIr  0.91 0.458 0.022 
PDILT PDIA7 0.93 0.507 0.024 
ERP44 PDIA10, TXNDC4 1.34 0.001* 0.001 
TXNDC12 ERP18, PDIA16, ERP19 1.17 0.035 0.006 
TMX1 TMX, PDIA11 1.06 0.589 0.026 
TMX2 PDIA12 1.26 0.021 0.005 
TMX3 PDIA13 0.96 0.755 0.033 
TMX4 PDIA14 0.90 0.297 0.016 
PDIA6 P5, ERP5, TXNDC7 1.42 0.002 0.002 
ERO1LB  ERO1B 1.60 0.003 0.002 
ERO1L  ERO1A 0.79 0.004 0.002 
P4HB PDIA1, ERP59 0.95 0.668 0.029 
ERP29 PDIA9, ERP28, ERP31 0.67 <0.001* 0.001 
PPIB CyclophilinB, CYPB 1.00 0.987 0.049 
FKBP2 FKBP13 1.05 0.717 0.032 
FKBP7 FKBP23 1.47 <0.001* 0.001 
FKBP10 FKBP65 0.74 0.002 0.002 
FKBP11 FKBP19 1.14 0.370 0.019 
          
N-linked Glycosylation(Lecca, Wagner et al. 2005, Schroder and Kaufman 2005) 
UGGT1 UGT1 1.00 0.973 0.047 
UGGT2 UGT2 1.09 0.478 0.023 
SDF2    1.50 0.003 0.002 
SDF2L1   2.41 <0.001* <0.001 
MOGS alpha glucosidase I 1.11 0.366 0.019 
GANAB alpha glucosidase II 0.80 0.006 0.003 
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MAN1A1 alpha mannosidase I 0.99 0.953 0.046 
MAN2A1 alpha mannosidase II 0.81 0.023 0.005 
ALG12                   1.29 0.008 0.003 
ALG5 1.30 0.006 0.003 
PIGA                     GPI3 1.35 0.012 0.004 
PIGB                      0.87 0.169 0.012 
RPN1 OST1                     1.01 0.942 0.045 
STT3A STT3, ITM1         0.90 0.226 0.014 
DDOST WBP1   0.95 0.653 0.029 
          
Human Chaperones(Kampinga, Hageman et al. 2009)   
HSPA (Hsp70 chaperones)       
HSPA1A   5.05 <0.001* <0.001 
HSPA1L   4.40 <0.001* <0.001 
HSPA2   1.37 0.005 0.003 
HSPA5 BiP, GRP78 2.62 <0.001* <0.001 
HSPA6   1.65 0.004 0.002 
HSPA7   1.65 0.004 0.002 
HSPA8   1.17 0.021 0.005 
HSPA9   1.00 0.977 0.048 
HSPA12A   0.92 0.381 0.019 
HSPA12B   0.96 0.680 0.030 
HSPA13   1.05 0.715 0.031 
HSPA14   1.26 0.007 0.003 
          
HSPH (Hsp110 chaperones)       
HYOU1 GRP170 1.79 <0.001* 0.001 
HSPH1   2.70 <0.001* <0.001 
HSPA4   1.48 <0.001* <0.001 
HSPA4L   1.56 <0.001* <0.001 
          
HSPC (Hsp 90 chaperones)       
HSP90AA1   1.43 <0.001* <0.001 
HSP90AA2   1.81 <0.001* <0.001 
HSP90AB1   1.06 0.651 0.029 
HSP90B1 GRP94 1.49 <0.001* <0.001 
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TRAP1   0.82 0.016 0.004 
          
DnaJA (Hsp40 co-chaperones)       
DNAJA1   1.62 <0.001* <0.001 
DNAJA2   1.14 0.121 0.010 
DNAJA3   1.12 0.169 0.012 
DNAJA4   0.99 0.938 0.044 
          
DnaJB (Hsp40 co-chaperones)       
DNAJB1   3.23 <0.001* <0.001 
DNAJB2   0.90 0.376 0.019 
DNAJB3   0.93 0.517 0.024 
DNAJB4   2.09 <0.001* <0.001 
DNAJB5   1.10 0.321 0.017 
DNAJB6   1.22 0.018 0.004 
DNAJB7   0.99 0.921 0.043 
DNAJB8   0.90 0.217 0.014 
DNAJB9   1.78 0.003 0.002 
DNAJB11   2.21 <0.001* <0.001 
DNAJB12   0.99 0.961 0.046 
DNAJB13   1.00 0.963 0.047 
DNAJB14   1.04 0.721 0.032 
          
DnaJC (Hsp40 co-chaperones)       
DNAJC1   0.97 0.834 0.037 
DNAJC2  MPP11 1.19 0.021 0.005 
DNAJC3  ERdj6 2.21 <0.001* <0.001 
DNAJC4   0.82 0.020 0.005 
DNAJC5   1.05 0.693 0.030 
DNAJC5B   0.99 0.946 0.045 
DNAJC5G   1.00 0.984 0.049 
DNAJC6   1.31 0.006 0.003 
DNAJC7   1.10 0.223 0.014 
DNAJC8   1.55 0.001* 0.001 
DNAJC9   1.22 0.028 0.005 
DNAJC10  ERdj5 0.82 0.015 0.004 
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DNAJC11   1.38 0.008 0.003 
DNAJC12   1.11 0.372 0.019 
DNAJC13   0.96 0.781 0.035 
DNAJC14   1.01 0.924 0.043 
DNAJC15   0.98 0.874 0.040 
DNAJC16   0.80 0.015 0.004 
DNAJC17   #N/A #N/A #N/A 
DNAJC18   0.75 0.001* 0.001 
DNAJC19  TIMM14 0.98 0.897 0.041 
DNAJC21   1.03 0.769 0.034 
DNAJC22   0.98 0.868 0.039
DNAJC24  DPH4 1.15 0.112 0.010 
DNAJC25   1.19 0.023 0.005 
DNAJC27   1.12 0.349 0.018 
DNAJC28   0.96 0.703 0.031
DNAJC30   0.99 0.972 0.047 
HSCB   1.04 0.776 0.034 
SEC63  ERdj2 0.91 0.343 0.018 
GAK  DNAJC26 1.06 0.638 0.028
SACS  DNAJC29 1.10 0.328 0.017 
          
HspB (small heat shock proteins)       
HSPB1  HSP25 1.90 0.001* 0.001 
HSPB2  HSP27 0.93 0.532 0.024 
HSPB3  HSPL27 1.07 0.611 0.027 
HSPB6  HSP20 #N/A #N/A #N/A 
HSPB7   0.92 0.466 0.022 
HSPB8   1.42 0.121 0.010 
HSPB9   0.91 0.356 0.018 
HSPB11   1.11 0.290 0.016 
HSPBAP1   1.18 0.049 0.007 
CRYAA   0.88 0.224 0.014 
CRYAB   1.03 0.811 0.036 
          
Chaperonin (Hsp10 and 60)       
HSPD1 HSP60, GROEL 1.15 0.036 0.006 
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HSPD1P1   1.36 0.010 0.003 
HSPE1 HSP10, GROES 1.58 <0.001* <0.001 
MKKS   0.99 0.940 0.045 
BBS10   1.30 0.012 0.004 
BBS12   1.15 0.260 0.015 
          
Chaperone regulator       
STIP1   1.72 <0.001* <0.001 
          
CLIPs (ribosome-associated chaperones)       
TCPA1   1.19 0.005 0.003 
CCT2   1.07 0.525 0.024 
CCT3   1.13 0.133 0.010 
CCT4   1.10 0.264 0.015 
CCT5   1.14 0.047 0.007 
CCT6A   1.26 <0.001* 0.001 
CCT6B   0.97 0.855 0.039 
CCT7   1.13 0.089 0.009 
CCT8   1.10 0.292 0.016 
PFDN1   1.22 0.007 0.003 
PFDN2   1.15 0.088 0.009 
VBP1   1.29 0.009 0.003 
PFDN4   1.21 0.048 0.007 
PFDN5   0.99 0.963 0.047 
PFDN6   1.48 <0.001* 0.001 
DNAJC2   1.19 0.021 0.005 
HSPA14   1.26 0.007 0.003 
BTF3   1.01 0.956 0.046 
NACA   1.01 0.955 0.046 
          
Peptidylprolyl cis-trans Isomerases (PPI)(Gerard, Deleersnijder et al. 2011, Benham 2012) 
FKBP1A   1.04 0.056 0.007 
FKBP1B   1.14 0.197 0.013 
FKBP2   1.05 0.717 0.032 
FKBP3   1.04 0.723 0.032 
FKBP4   1.50 <0.001* 0.001 
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FKBP5   1.27 0.003 0.002 
FKBP6   0.88 0.206 0.013 
FKBP7   1.47 <0.001* 0.001 
FKBP8   0.97 0.817 0.036 
FKBP9   0.83 0.060 0.007 
FKBP9L   0.81 0.023 0.005 
FKBP10   0.74 0.002 0.002 
FKBP11   1.14 0.370 0.019 
FKBP14   1.46 0.001* 0.001 
FKBPL   1.02 0.843 0.038 
PIN1   1.15 0.073 0.008
PIN1P1   #N/A #N/A #N/A 
PIN4   1.18 0.154 0.011 
PPIA   1.08 0.418 0.020 
PPIAL4A   1.02 0.927 0.044
PPIAL4B   1.00 0.927 0.044 
PPIAL4C   1.00 0.927 0.044 
PPIAL4D   #N/A #N/A #N/A 
PPIAL4E   1.00 0.927 0.044
PPIAL4F   1.00 0.927 0.044 
PPIAL4G   0.97 0.908 0.042 
PPIB CyclophilinB, CYPB 1.00 0.987 0.049 
PPIC   0.92 0.432 0.021
PPID   1.59 <0.001* 0.001 
PPIE   1.19 0.077 0.008 
PPIEL   1.04 0.949 0.045 
PPIF   1.00 0.992 0.049
PPIG   1.45 <0.001* 0.001 
PPIH   1.37 <0.001* <0.001 
PPIL1   1.17 0.045 0.007 
PPIL2   0.82 0.010 0.003
PPIL3   0.91 0.304 0.017 
PPIL4   1.42 0.001* 0.001 
PPIL6   0.85 0.095 0.009 
PPWD1   1.10 0.325 0.017 
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Protein Disulfide Isomerases (PDI)11 
PDIA2   0.91 0.458 0.022 
PDIA3   1.36 0.001* 0.002 
PDIA4   2.55 <0.001* <0.001 
PDIA5   0.97 0.832 0.037 
PDIA6   1.42 0.002 0.002 
PDILT   0.93 0.507 0.024 
PDIK1L   0.93 0.502 0.023 
P4HB   0.95 0.668 0.029 
ERP27   0.97 0.880 0.040 
ERP29   0.67 <0.001* 0.001
ERP44   1.34 0.001* 0.001 
TMX1   1.06 0.589 0.026 
TMX2   1.26 0.021 0.005 
TMX3   0.96 0.755 0.033
TMX4   0.90 0.297 0.016 
TXNDC5   1.21 0.274 0.016 
TXNDC12   1.17 0.035 0.006 
AGR2   1.07 0.528 0.024
AGR3   0.97 0.898 0.041 
DNAJC10   0.82 0.015 0.004 
CASQ1   0.98 0.930 0.044 
CASQ2   0.92 0.397 0.020
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